M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page. The draft guidance has been left in the original International Council for Harmonisation format. The final guidance will be reformatted and edited to conform with FDA's good guidance practice regulation and style.

For questions regarding this draft document contact (CDER) Aisar Atrakchi 301-796-1036.

FOREWORD

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has the mission of achieving greater regulatory harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed, registered, and maintained in the most resource-efficient manner. By harmonizing the regulatory expectations in regions around the world, ICH guidelines have substantially reduced duplicative clinical studies, prevented unnecessary animal studies, standardized safety reporting and marketing application submissions, and contributed to many other improvements in the quality of global drug development and manufacturing and the products available to patients.

ICH is a consensus-driven process that involves technical experts from regulatory authorities and industry parties in detailed technical and science-based harmonization work that results in the development of ICH guidelines. The commitment to consistent adoption of these consensus-based guidelines by regulators around the globe is critical to realizing the benefits of safe, effective, and high-quality medicines for patients as well as for industry. As a Founding Regulatory Member of ICH, the Food and Drug Administration (FDA) plays a major role in the development of each of the ICH guidelines, which FDA then adopts and issues as guidance to industry.

INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH)

ICH HARMONISED GUIDELINE

APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO
CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES

Addendum to M7(R2)

Draft version

Endorsed on 6-Oct-21

Currently under public consultation

At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

Addendum to M7(R2)
Document History

Current *Step 2* version

M7(R2) Addendum	Endorsement by the Members of the ICH Assembly under *Step 2* and release for public consultation	6-Oct-21

List of Changes to the M7 Guideline and Addendum, When Finalized:

1. The M7 document will be physically separated into a main Guideline and a separate Addendum including the monographs;

2. In the main M7 Guideline, the HIV duration will be changed from ">1-10 years to >10 years" to "lifetime." This change is addressed in the "M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk--Questions and Answers" document;

3. In the main M7 Guideline, the monograph table will be edited to include the 7 new monographs;

4. In the Addendum, 7 new monographs and 1 note will be added (see pages 4-51 of this document):

   a. Acetaldehyde, Dibromoethane, Epichlorohydrin, Ethyl Bromide, Formaldehyde, Styrene, Vinyl Acetate;

   b. Note 4;

5. In the main M7 Guideline and Addendum, standard grammatical and formatting edits will be made;

6. In the main M7 Guideline, the final sentence of Note 1 will be edited for clarification as follows: "In cases where the amount of the impurity is less than or equal to 1 mg, no further genotoxicity testing is required regardless of other qualification thresholds."

Acceptable Intakes (AIs) or Permissible Daily Exposures (PDEs)

Compound	CAS#	Chemical Structure	AI or PDE (µg/day)	Comment
Linear extrapolation from TD$_{50}$				
Acrylonitrile	107-13-1		6	TD$_{50}$ linear extrapolation
Benzyl chloride	100-44-7		41	TD$_{50}$ linear extrapolation
Bis(chloromethyl)ether	542-88-1		0.004	TD$_{50}$ linear extrapolation
1-Chloro-4-nitrobenzene	100-00-5		117	TD$_{50}$ linear extrapolation
p-Cresidine	120-71-8		45	TD$_{50}$ linear extrapolation
1,2-Dibromoethane	106-93-4		2	TD$_{50}$ linear extrapolation
Dimethylcarbamyl Chloride	79-44-7		0.6 (inhalation)* 5 (all other routes)	TD$_{50}$ linear extrapolation
Epichlorohydrin	106-89-8		3	TD$_{50}$ linear Extrapolation
Ethyl bromide	74-96-4		32	TD$_{50}$ linear Extrapolation
Ethyl chloride	75-00-3		1,810	TD$_{50}$ linear extrapolation
Glycidol	556-52-5		4	TD$_{50}$ linear extrapolation
Hydrazine	302-01-2		0.2 (inhalation)* 39 (all other routes)	TD$_{50}$ linear extrapolation
Methyl Chloride	74-87-3		1,361	TD$_{50}$ linear extrapolation
Styrene	100-42-5		154	TD$_{50}$ linear extrapolation
Threshold-based PDE				

Aniline Aniline HCl	62-53-3 142-04-1	(structure of aniline, benzene ring with NH_2)	720	PDE based on threshold mode of Action (hemosiderosis)
Endogenous and/or Environmental Exposure				
Acetaldehyde	75-07-0	(structure of acetaldehyde, H–$C(=O)$–CH_3)	2,000 (oral)* 185 (all other routes)	Oral PDE is based on average food intake; all other routes based on TD_{50} linear extrapolation from an inhalation study
Formaldehyde	50-00-0	(structure of formaldehyde, H–$C(=O)$–H)	8,000 or 215 ppb, whichever is lower (inhalation)* 10,000 (all other routes)	Inhalation route based on TD_{50} linear extrapolation or local irritation; all other routes based on average food intake
Hydrogen peroxide	7722-84-1	HO–OH	68,000 or 0.5%, whichever is lower	68 mg/day is 1% of estimated endogenous production
Vinyl acetate	108-05-4	(structure of vinyl acetate, H_3C–$C(=O)$–O–CH_2)	2,000 (oral)* 758 (all other routes)	Oral PDE is based on average food intake for acetaldehyde; all other routes based on TD_{50} linear extrapolation from an inhalation study
Other Cases				
p-Chloroaniline *p*-Chloroaniline HCl	106-47-8 20265-96-7	(structure of p-chloroaniline, benzene ring with NH_2 and Cl)	34	AI based on liver tumors for which mutagenic mode of action cannot be ruled out
Dimethyl Sulfate	77-78-1	(structure of dimethyl sulfate, H_3C–O–$S(=O)_2$–O–CH_3)	1.5	Carcinogenicity data available, but inadequate to derive AI. Default to TTC

* route specific limit

24

Acetaldehyde (CAS# 75-07-0)

Potential for human exposure

Acetaldehyde is formed endogenously in the human body from the metabolism of ethanol and carbohydrates as well as from bacteria in the alimentary tract. Humans are exposed to acetaldehyde mainly in food, alcoholic beverages, cigarette smoke and to a lesser extent from environmental emissions (Ref. 1, 2). The determination of endogenous acetaldehyde in blood, breath and saliva is challenging as the techniques are prone to artifacts and contaminants (Ref. 3, 4). Nevertheless, a daily endogenous production of 360 mg/day of acetaldehyde was calculated based on a constant endogenous total acetaldehyde concentration in the blood of 2.2 ±1.1 μmol/L (Ref. 3) and acetaldehyde clearance of 0.95 L/min (Ref. 5). Average acetaldehyde consumption of up to 48 mg/day comes from consumption of alcoholic beverages (Ref. 6). Endogenous acetaldehyde concentrations and the associated cancer risk are significantly higher in individuals with an ALDH2 genetic polymorphism (Ref. 7). The exogenous exposure from food (without alcoholic beverages or added acetaldehyde as flavoring agent) was estimated to be around 2 mg/day on average and 8 mg/day for the upper 95% of the German population (Ref. 8), JECFA estimated food additive consumption to be 9.7 mg/day in the USA and 11 mg/day in Europe although this estimate is restricted to consumers who eat foods in which acetaldehyde is added as a flavor (Ref. 9) and the Japanese Food Safety Committee estimated domestic consumption between 9.6 – 19.2 mg/day (Ref. 10). Acetaldehyde is used in synthesis of pharmaceuticals.

Mutagenicity/genotoxicity

The genotoxicity of acetaldehyde has been previously reviewed by the Chemical Evaluation and Research Institute and others (Ref. 1, 5, 11-18). Acetaldehyde was negative in comprehensive bacterial Ames reverse mutation assays, but induced increases in mutations at the hypoxanthine-guanine-phosphoribosyl transferase (*hprt*) locus in mammalian cells, which included point mutations demonstrated by sequencing (Ref. 13). DNA- and DNA-protein adducts were observed in cultured cells treated with acetaldehyde and DNA adducts were measured in urine of healthy volunteers and in blood cells from persons who abuse alcohol. Acetaldehyde is primarily an inducer of larger scale chromosomal effects. It induces chromosomal aberrations and micronuclei *in vitro* and was positive in the mouse lymphoma L5178Y *tk*+/- assay. Acetaldehyde induced increases in micronuclei in the bone marrow of rats and mice.

Carcinogenicity

Acetaldehyde is an IARC 2B carcinogen and "acetaldehyde associated with the consumption of alcoholic beverages" is an IARC 1 carcinogen, i.e. "carcinogenic to humans." Acetaldehyde was carcinogenic in rats and hamsters after inhalation exposure (Ref. 1).

In humans, acetaldehyde is the primary metabolite of alcohol and high as well as low alcohol consumption has been correlated with an increased relative risk for certain human cancers (e.g. oral cavity, pharynx cancer and breast cancer) (Ref. 19, 20). The relative risk was increased in smokers showing a tobacco-alcohol synergism and a possible contribution of acetaldehyde derived from cigarette smoke (Ref. 19). Also, geographical regions with consumption of alcoholic beverages containing high acetaldehyde concentrations showed a tendency for higher incidence of squamous-cell cancer and cancer of the esophagus (Ref. 21). Furthermore, available epidemiological data indicate that there is an increased risk for development of alcohol-related cancers for those individuals who are deficient in detoxifying acetaldehyde to acetate by ALDH. Especially the genetic variant ALDH2*1/*2 is strongly associated with alcohol-related cancers in not only heavy drinkers but those with moderate levels of alcohol consumption (Ref. 1, 5, 19).

Meta analyses and large cohort studies report conflicting conclusions about whether there are increased risks of head, neck and mammary tumors associated with moderate alcohol consumption in the U.S. populations where ALDH deficiency is relatively infrequent (Ref. 22, 23). The literature on the elevated risk of head and neck cancers associated with acetaldehyde exposure in heavy drinkers, smokers, and in moderate drinkers with ALDH deficiency does not include discussion of whether those exposures are also associated with histopathological changes consistent with irritation or tissue proliferation.

In rodents, only inhalation carcinogenicity studies are available in the Carcinogenic Potency Database (CPDB) (Ref. 24). The most robust study was conducted with Wistar rats (Ref. 25) with whole-body inhalation exposure to 0, 750, 1500 or 3000/1000 ppm (reduced after 11 months due to toxicity), 6 h/day at 5 days/week for up to 28 months. The doses shown in the CPDB were 0, 70.8, 142 and 147 mg/kg for male rats and 0, 101, 202 and 209 mg/kg for female rats. In the high-dose group, 50% of the male and 42% of the female animals had died by week 67 and no high-dose animals were alive by week 102. An increased incidence of tumors at the site of contact, i.e. nasal squamous cell carcinomas, was observed in males (1/49, 1/52, 10/53 and 15/49 corresponding to control, low, mid and high dose groups) and females (0/50, 0/48, 5/53 and 17/53, respectively) at the end of the study. There were also increases in nasal adenocarcinomas at all doses, the incidences were 0/49, 16/52, 31/53 and 21/49 in males and 0/50, 6/48, 26/53 and 21/53 in females, respectively. Based on these data, the TD_{50} value shown in the CPDB was estimated to be 185 mg/kg for nasal adenocarcinoma in male rats in the most sensitive sex and tissue.

An oral carcinogenicity study (Ref. 26) was conducted in Sprague Dawley rats with acetaldehyde administration in drinking water. In this study, 50 rats per group were given 0, 50, 250, 500, 1500 and 2500 mg/L acetaldehyde in drinking water for 104 weeks and the experiment was terminated when the last animal died at 161 weeks of age. The concentrations correspond to 0, 5, 25, 49, 147 and 246 mg/kg/day for male rats and 0, 5, 27, 53, 155 and 260 mg/kg/day for female rats, respectively. Incidences of adenocarcinomas, lymphomas and leukemias, mammary tumors, and cranial osteosarcomas, were described by the investigators as significantly greater in at least one group of exposed rats, relative to control. There was no increase in malignant tumors at the site of contact organs, i.e. the oral cavity and gastrointestinal tract, or in the liver.

This study suggests that acetaldehyde may be carcinogenic after intake via drinking water. However, there was no clear dose-response relationship and therefore, many evaluators found that no clear conclusion can be drawn from this study (Ref. 5, 12, 19). In another evaluation of the same data, two different dose-response models were used to estimate cancer potency and the authors concluded that their quantitative risk assessment indicates the need to lower acetaldehyde exposure in the general population but also acknowledged that naturally occurring acetaldehyde cannot be reduced (Ref. 21). In this model, the carcinogenic potency was calculated for all tumor bearing animals because the authors found that there was insufficient statistical power to generate a model for any specific cancer site. A TD_{50} related to oral administration of acetaldehyde was not calculated.

118 **Acetaldehyde – Details of carcinogenicity studies**

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/sex	TD_{50} (mg/kg/d)
Ref. 26	50/sex/ group Sprague Dawley rat	24 months, drinking water	50	**5:** M: 5, 25, 49, 147 and 246 mg/kg/d F: 5, 27, 53, 155 and 260 mg/kg/d	Not identifiable	NC[a]
Ref. 25	55/sex/ group Wistar rat	28 months, Inhalation	55	**3:** M: 70.8, 142, 147 mg/kg/d F: 101, 202, 209 mg/kg/d	Male Nasal adenocarcinoma	185[b]
Ref. 27	30/sex/ group Syrian golden hamster	52 weeks, Inhalation	30	**1:** M: 344 mg/kg/d, F: 391 mg/kg/d	Male Larynx	461[c]

119 Studies listed are in Cancer Potency Database (CPDB) (Ref. 24)
120 NC = not calculated;
121 [a] Not in CPDB and given the lack of dose-response and insufficient statistical power no TD_{50} was
122 calculated.
123 [b] TD_{50} taken from the CPDB
124 [c] In CPDB but not used in evaluation because of small group size and single treatment group.
125

126 **Mode of action for carcinogenicity**

127 Acetaldehyde is a strong electrophile and is capable of reacting with strong nucleophiles, for
128 example DNA bases or amino acid residues on proteins. Although not mutagenic in the standard
129 bacterial reversion assay, evidence for DNA-reactivity and mutagenicity was shown for
130 acetaldehyde by the presence of DNA and DNA-protein adducts *in vitro* and *in vivo*, as well as
131 the positive result in the *in vitro hprt* mutagenicity assay in mammalian cells. Despite its reactive
132 nature, there is evidence for a non-linear dose response associated with the genotoxicity and
133 carcinogenicity of acetaldehyde (Ref. 14). The dose-response of acetaldehyde-induced adducts at
134 concentrations between 1 and 1000 uM has been measured in a cell culture system allowing the
135 discrimination between endogenous and exogenous adducts induced by added acetaldehyde.
136 These concentrations are comparable to salivary acetaldehyde concentrations measured before
137 and after consumption of beverages containing alcohol with or without acetaldehyde (Ref. 28, 29).
138 The exogenous adducts only exceeded the endogenous background level of adducts above a
139 critical concentration.

140 Aldehyde hydrogenase (ALDH), which efficiently detoxifies acetaldehyde, is responsible for the
141 non-linear dose response relationship. ALDH enzymes are expressed in the mitochondria and
142 cytosol of most tissues (e.g., liver, gastrointestinal tract, kidneys, nasal epithelium/olfactory
143 epithelium, lung) and they metabolize acetaldehyde to form acetate and one proton (Ref. 30). The

release of protons can reduce cellular pH and thus cause non-specific cytotoxicity with subsequent proliferative effects. The importance of detoxification is shown in ALDH deficient animal models. For example, acetaldehyde induced chromosome damage and mutation is observed in mice deficient in ALDH2 activity following inhalation and oral (gavage) exposure, but not in ALDH2-proficient mice (Ref. 31). Similarly, more acetaldehyde derived DNA adducts were seen in alcoholics with a deficient aldehyde dehydrogenase genotype (allelic variant type ALDH2*1/2*2 with about 10% residual ALDH activity) compared to those with efficient genotype ALDH2*1/2*1 (Ref. 32) and moderate drinkers with the genotype are at increased risk of head and neck cancers (IARC).

The inhalation carcinogenicity data and mechanistic study data suggest that acetaldehyde cancer risk is highest at and possibly limited to the site-of-contact. The nasal tumors in inhalation carcinogenicity studies were only found at inhalation doses also associated with cytotoxicity and severe irritation causing regenerative proliferation consistent with the hypothesis that there could be promotion of growth of mutated cells (Ref. 5, 14). Detoxification of acetaldehyde by ALDH in airway cells may make tumor induction less likely at lower, non-irritating doses. However, there are no published measurements which would allow discrimination between the irritating effect and the potential mutagenic effect in cancer development.

Regulatory and/or published limits

Acetaldehyde is listed in the US Food and Drug Administration's (FDA's) 'generally recognized as safe' (GRAS) list for flavoring substances and adjuvants – 21 CFR 182.60. The Japanese FSC confirmed the absence of safety concerns when used as a flavoring agent as it is completely metabolized into non-reactive acetic acid and finally CO_2, and thus, its level as a flavoring agent is presumed not to exceed the physiological range (Ref. 10). The Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluation has concluded that there are no safety concerns at current levels of intake when used as a flavoring agent, which was 11 mg/day in Europe and 9.7 mg/day in the United States (Ref. 9).

The Committee on Emergency and Continuous Exposure Guidance Levels for Selected Submarine Contaminants (Ref. 33) recommended a Continuous Exposure Guidance Level (CEGL) of 2 ppm corresponding to 3.6 mg/m^3. This represents an exposure of 3.6 mg/m^3 x 28.8 m^3 (24 hours in a day – ICH Q3C assumption) = 104 mg/day.

The US EPA did not consider a threshold for acetaldehyde carcinogenicity and has calculated that a concentration of 5 μg/m^3 acetaldehyde represents a 10^{-5} excess lifetime cancer risk based on the rat inhalation carcinogenicity study and application of linear extrapolation (Ref. 34). For a 24 h exposure, this represents 5 μg/m^3 x 28.8 m^3 = 144 μg/day. EPA did not consider the risk via the oral route.

Permissible Daily Exposure (PDE) for oral exposure

<u>Rationale for selection of study for PDE calculation</u>

Given the weight of evidence for a non-linear dose-response for the carcinogenicity of acetaldehyde following oral administration and high background exposure from a wide variety of foods, a permissible daily exposure (PDE) of 2 mg/day is identified for oral limit based on the estimated average intake of acetaldehyde from food around 2 mg/day (Ref. 8).

PDE (oral) = 2 mg/day

Acceptable intake (AI) for all other routes

Rationale for selection of study for AI calculation

The inhalation study in rats by Woutersen et al. (Ref. 25) was used to derive the AI for all other routes. This study comprises group sizes of 50/sex/dose and animals were treated for lifetime (i.e., 24 months). According to M7's recommendations for selecting the most relevant study for deriving an AI, this is considered the most appropriate and robust study available for acetaldehyde. The inhalation carcinogenicity data and mechanistic study data suggest acetaldehyde cancer risk to be associated with cytotoxicity at the site of contact as nasal tumors were only found at doses also associated with cytotoxicity and severe irritation causing regenerative proliferation and promotion of growth of mutated cells.

Calculation of AI

Lifetime AI = TD_{50}/50000 x 50 kg

Lifetime AI = 185 mg/kg/day/50000 x 50 kg

Lifetime AI (all other routes) = 185 µg/day

References

1. IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Acetaldehyde. 1999;71:319–35.

2. O'Brien PJ, Siraki AG, et al. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 2005;35:609-62.

3. Fukunaga T, Sillanaukee P, Eriksson CJP. Problems involved in the determination of endogenous acetaldehyde in human blood. Alcohol and Alcoholism 1993;28:535-541.

4. Jones AW. Measuring and reporting the concentration of acetaldehyde in human breath. Alcohol and Alcoholism 1995;30:271-285.

5. Maximum Workplace Concentration Commission (MAK). The MAK Collection for Occupational Health and Safety. Acetaldehyde. 2013;1–58.

6. Lachenmeier DW, Gill JS, Chick J, Rehm J. The total margin of exposure of ethanol and acetaldehyde for heavy drinkers consuming cider or vodka. Food Chem Toxicol 2015;83:210–214.

7. Väkeväinen S, Tillonen J, Agarwal DP, Srivastava N, Salaspuro M. High salivary acetaldehyde after a moderate dose of alcohol in ALDH2-deficient subjects: strong evidence for the local carcinogenic action of acetaldehyde. Alcohol Clin Exp Res 2000;24:873-7.

8. Uebelacker M, Lachenmeier DW. Quantitative determination of acetaldehyde in foods using automated digestion with simulated gastric fluid followed by headspace gas chromatography. J Autom Methods Manag Chem 2011;2011:907317.

232   9. Joint FAO/WHO Expert Committee on Food Additives (JECFA). Evaluation of certain
233   food additives and contaminants. Forty-Ninth Report of the Joint FAO/WHO Expert
234   Committee on Food Additives. 1999; WHO Technical Report Series 884.

235   10. Food Safety Commission (FSC). Evaluation of Food Additives: Acetaldehyde, Tokyo,
236   Japan. 2005.

237   11. Chemicals Evaluation and Research Institute Japan (CERI). Hazard Assessment Report
238   Acetaldehyde, Japan. 2007.

239   12. European Commission (EC). Scientific Committee on Consumer Safety: SCCS/1468/12:
240   Opinion On: Acetaldehyde. 2012; SCCS/1468/12.

241   13. Scientific Committee on Cosmetic Products and Non-Food Products (SCCNFP). Opinion
242   of the Scientific Committee on Cosmetic Products and non-food products for consumers
243   concerning acetaldehyde. 2004; SCCNFP/0821/04.

244   14. Albertini RJ. Vinyl acetate monomer (VAM) genotoxicity profile: Relevance for
245   carcinogenicity. Critical Reviews in Toxicology 2013;43:671-706.

246   15. Grafström RC, Dypbukt JM, Sundqvist K, Atzori L, Nielsen I, Curren RD, Harris CC.
247   Pathobiological effects of acetaldehyde in cultured human epithelial cells and fibroblasts.
248   Carcinogenesis 1994;15:985–990.

249   16. Moeller BC, Recio L, Green A, Sun W, Wright FA, Bodnar WM, Swenberg JA.
250   Biomarkers of Exposure and Effect in Human Lymphoblastoid TK6 Cells Following
251   [^{13}C$_2$]-Acetaldehyde Exposure. Toxicological Sciences 2013;133:1-12.

252   17. Morita T, Asano N, Awogi T, Sasaki YF, Sato S-I, Shimada H, Sutou S, Suzuki T,
253   Wakata A, Sofuni T, Hayashi M. Evaluation of the rodent micronucleus assay in the
254   screening of IARC carcinogens (groups 1, 2A and 2B). The summary report of the 6th
255   collaborative study by CSGMT/JEMS MMS. Mutation Research 1997;389:3–122

256   18. Speit G, Froehler-Keller M, Schuetz P, Neuss S. Low sensitivity of the comet assay to
257   detect acetaldehyde-induced genotoxicity. Mutation Research 2008;657:93–97.

258   19. IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to
259   humans. Personal habits and indoor combustions. 2012; Volume 100 E.

260   20. Shield KD, Soerjomataram I, Rehm J. Alcohol Use and Breast Cancer: A Critical
261   Review. Alcohol Clin Exp Res 2016;40:1166-81.

262   21. Lachenmeier DW, Kanteres F, Rehm J. Carcinogenicity of acetaldehyde in alcoholic
263   beverages: risk assessment outside ethanol metabolism. Addiction 2009;104:533-50.

264   22. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M,
265   Turati F, Pasquali E, Pelucchi C, Galeone C, Bellocco R, Negri E, Corrao G, Boffetta P,
266   La Vecchia C. Alcohol consumption and site-specific cancer risk: a comprehensive dose-
267   response meta-analysis. Br J Cancer 2015;112:580-93.

268   23. Cao L, Tan L, Wang HF, Jiang T, Zhu XC, Lu H, Tan MS, Yu JT. Dietary Patterns and
269   Risk of Dementia: a Systematic Review and Meta-Analysis of Cohort Studies. Mol
270   Neurobiol 2016;53:6144-6154.

271   24. Carcinogenicity Potency Database (CPDB). [Online]. Available from: URL:
272   https://files.toxplanet.com/cpdb/index.html

273   25. Woutersen RA, Appelman LM, Van Garderen-Hoetmer a and Feron VJ. Inhalation
274   toxicity of acetaldehyde in rats. III. Carcinogenicity study. Toxicology 1986;41:213-231.

275   26. Soffritti M, Belpoggi F, Lambertini L, Lauriola M, Padovani M, Maltoni C. Results of
276   long-term experimental studies on the carcinogenicity of formaldehyde and acetaldehyde
277   in rats. Ann N Y Acad Sci 2002;982:87–105.

278   27. Feron VJ, Kruysse A, Woutersen RA. Respiratory tract tumours in hamsters exposed to
279   acetaldehyde vapour alone or simultaneously to benzo(a)pyrene or diethylnitrosamine.
280   European Journal of Cancer Clinical Oncology 1982;1:13-31.

281   28. Homann N, Jousimies-Somer H, Jokelainen K, Heine R, Salaspuro M. High
282   acetaldehyde levels in saliva after ethanol consumption: methodological aspects and
283   pathogenetic implications. Carcinogenesis 1997;18:1739-43.

284   29. Salaspuro V, Hietala J, Kaihovaara P, Pihlajarinne L, Marvola M, Salaspuro M. Removal
285   of acetaldehyde from saliva by a slow-release buccal tablet of L-cysteine. Int J Cancer
286   2002;97:361-4.

287   30. Sladek NE. Human aldehyde dehydrogenases: Potential pathological, pharmacological
288   and toxicological impact. Journal of Biochemical Molecular Toxicology 2003;17:8-23.

289   31. Kunugita N, Isse T, Oyama T, Kitagawa K, Ogawa M, Yamaguchi T, Kinaga T and
290   Kawamoto T. Increased frequencies of micronucleated reticulocytes and T-cell receptor
291   mutation in ALDH2 knockout mice exposed to acetaldehyde. Journal of Toxicological
292   Science 2008;33:31-6.

293   32. Matsuda T, Yabushita H, Kanaly RA, Shibutani S, Yokoyama A. Increased DNA
294   damage in ALDH2-deficient alcoholics. Chemical Research in Toxicology
295   2006;19:1374-1378.

296   33. Committee on Emergency and Continuous Exposure Guidance Levels for Selected
297   Submarine Contaminants (CECEGL). Emergency and continuous exposure guidance
298   levels for selected submarine contaminants, Volume 3, National Academies Press,
299   Washington. 2009.

300   34. United States Environmental Protection Agency (USEPA). Integrated Risk Information
301   System (IRIS). Acetaldehyde (CASRN 75-07-0) Carcinogenicity Assessment. 1988;
302   Available from: URL:
303   https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0290_summary.pdf

304

305

306

1,2-Dibromoethane (CAS# 106-93-4)

Potential for human exposure

1,2-Dibromoethane was previously used as an insect fumigant and soil nematocide but was banned by the U.S. EPA and the EC due to toxicity concerns (Ref. 1, 2). 1,2-Dibromoethane is used in the synthesis of active pharmaceutical ingredients.

Mutagenicity/genotoxicity

1,2-Dibromoethane is mutagenic/genotoxic *in vitro* and *in vivo*. The mutagenicity of 1,2-dibromoethane was evaluated in *Salmonella* tester strains TA 1535, TA 1537, TA 98, TA 100, TA 1538 and in E. coli WP2, both in the presence and absence of added metabolic activation by Aroclor-induced rat liver S9 fraction (Ref. 3-7). 1,2-Dibromoethane was mutagenic in *Salmonella typhimurium* strains TA 100, TA 1535, TA 98 and E. coli WP2, with and without metabolic activation. 1,2-Dibromoethane was positive in the mouse lymphoma assay, with and without metabolic activation (Ref. 8). It caused a dose-dependent increase in DNA repair in both spermatocytes and hepatocytes *in vitro* (Ref. 9) and induced mutations in Chinese hamster ovary (CHO) cells (Ref. 10). 1,2-Dibromoethane increased the frequencies of chromosome aberrations in a dose-dependent manner in CHO cells (Ref. 11). *In vivo* in the Comet assay in rats, positive results were obtained in liver and glandular stomach following treatment with 1,2-dibromoethane at 100 mg/kg. 1,2-Dibromoethane was negative in the bone marrow and erythrocyte micronucleus test in rats when tested up to 100 mg/kg (Ref. 12). At this dose, a 7% body weight reduction and 25 % reduction in immature erythrocytes was observed indicating slight to moderate toxicity.

Carcinogenicity

1,2-Dibromoethane is classified by IARC as probably carcinogenic to humans (Group 2A) (Ref. 13). Inhalation and oral carcinogenicity studies are cited in CPDB (Ref. 14). 1,2-Dibromoethane was carcinogenic following both routes of administration in male and female rats and mice (Table 1). The most sensitive tumor sites were forestomach following oral administration (gavage or drinking water) and nasal cavity following inhalation. Other tumor sites include blood vessels, lung, liver and mammary glands. There was more than one positive experiment in both species.

1,2-Dibromoethane – Details of carcinogenicity studies

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses*	Most sensitive tumor site/type/sex	TD_{50} (mg/kg/d)*
Ref. 16	30/sex/ group B6C3F1 mice	M: 65 weeks F: 73 weeks, drinking water	50	**1:** 4 mmol M: 116 mg/kg/d F: 103 mg/kg/d	Squamous carcinoma of forestomach	11.8
Ref. 17	50/sex/ group B6C3F1 mice	78 weeks, drinking water	100	**1:** M: 1.4 mg F: 1.2 mg	Forestomach papilloma	9.44

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses*	Most sensitive tumor site/type/sex	TD$_{50}$ (mg/kg/d) *
Ref. 18	50/sex/ group B6C3F1 mice	53 weeks, gavage	20	**2:** M: 26, 52 mg/kg/d F: 30, 53 mg/kg/d	Squamous-cell carcinomas of forestomach	2.36
Ref. 18	50/sex/ group Osborne-Mendel rats	M: 40 weeks F: 50 weeks, Gavage	20	**2:** M: 27.4, 29.2 mg/kg/d F: 26.7, 28.1 mg/kg/d	Squamous-cell carcinomas of forestomach	1.26
Ref. 19	50/sex/ group B6C3F1 mice	M: 78 weeks F: 96 weeks, Inhalation	50	**2:** M: 19.9, 79.5 mg/kg/d F: 23.9, 95.6 mg/kg/d	Alveolar/bronchiolar carcinomas and adenomas	18.2
Ref. 19	50/sex/ group F344 rats	M: 95 weeks F: 97 weeks, Inhalation	50	**2:** M: 4, 15.9 mg/kg/d F: 5.71, 22.8 mg/kg/d	Carcinomas, adenocarcinomas, adenomas of nasal cavity	2.33
Ref. 20	48/sex/ group Sprague-Dawley rats	78 weeks, inhalation	48	**1:** M: 9.39 mg/kg/d F: 13.4 mg/kg/d	Nasal cavity	1.19
Ref. 21	50/sex/ group B6C3F1 mice	103 weeks (10 ppm) / 90 weeks (40 ppm), Inhalation	50	**2:** 10, 40 ppm for 6 h/d, 5 d/wk	Focal epithelial hyperplasia	Not available

339 * mg/kg/d values stated in CPDB (Ref. 14) and calculated by method used to standardize average daily
340 dose levels from variety of routes of administration, dosing schedules, species, strains and sexes; values
341 stated in CPDB accounted for exposure duration of 24 h per day for 7 days per week. (Dose rate =
342 (administered dose × intake/day × number of doses/week) / (animal weight × 7 days/week))
343 * Individual TD$_{50}$ values are the CPDB TD$_{50}$ values as reported in the Lhasa carcinogenicity database
344 (Ref. 15). TD$_{50}$ values represent the TD$_{50}$ from the most sensitive tumor site.
345

346 **Mode of action for carcinogenicity**

347 1,2-Dibromoethane is a mutagenic carcinogen, which is expected to be mutagenic based on an
348 alkylating mechanism of action. Therefore, the acceptable intake can be calculated by linear
349 extrapolation from the TD$_{50}$. The tumor types with the lowest calculated TD$_{50}$ (highest potency)
350 for 1,2-dibromoethane following oral exposure are forestomach tumors in mice and rats (Ref 18).
351 Following inhalation exposure, the lowest calculated TD$_{50}$ values are associated with the lung and

nasal cavity for mice and rats, respectively. High concentrations of orally dosed non-mutagenic chemicals have been shown to cause inflammation and irritation after contact with the forestomach leading to hyperplasia and ultimately tumors. Substances that are dosed by gavage can remain for some time in the rodent forestomach before discharge to the glandular stomach, in contrast to the rapid passage through the human esophagus. Hence, such tumor induction is considered not relevant to humans at non-irritating doses (Ref. 22, 23). The same inflammatory and hyperplastic effects are also seen with mutagenic chemicals. However, in the case of 1,2-dibromoethane, which is a directly DNA reactive alkylating agent and reported multi-site, multi-species carcinogen, it is difficult to discriminate between the contribution to mode of action of these non-mutagenic, high-dose effects compared with direct mutation induction.

Regulatory and/or published limits

No regulatory limits have been published.

Acceptable intake (AI)

Rationale for selection of study for AI calculation

1,2-Dibromoethane is a mutagenic carcinogen via the inhalation and oral routes of exposure. 1,2-Dibromoethane is considered to be a carcinogen in both mice and rats. The available toxicological data indicate that absorption of inhaled 1,2-dibromoethane occurs in several animal species. In rats, oral absorption has been shown to be nearly complete within 30 minutes (Ref. 1). Therefore, it can be reasonably assumed that complete systemic exposure to 1,2-dibromoethane occurs following oral and inhalation exposure. This is also supported by the observation of distal tumors in animals exposed to 1,2-dibromoethane by both routes of exposure. TD_{50} values tend to be similar across species and route of administration.

The most appropriate and robust carcinogenicity data for derivation of an AI is the inhalation study conducted by the NTP (Ref. 19) in F344 rats. This study (duration 95 weeks in males and 97 weeks in females) included two test article treatment groups with adequate dose spacing (M: 4, 15.9 mg/kg/d, F: 5.71, 22.8 mg/kg/d with 50 rats/sex/group) and a control group (50/sex). Another study with inhalation exposure conducted in Sprague-Dawley rats (Ref. 20) resulted in a lower TD_{50}, however the study comprised only one dose group and only 78 weeks duration and 48 animals/dose and therefore was considered inferior to the NTP study with respect to AI calculation. Therefore, the TD_{50} value for the most sensitive species/sex/site of the most appropriate study is 2.33 mg/kg/d.

For the oral route of exposure the study in B6C3F1 mice with 1,2-dibromoethane administered by gavage for 53 weeks (Ref. 18) is the most extensive study. This study employed two test article dose groups (50 sex/group) in addition to a control group (20 sex). The TD_{50} from the most sensitive sex and site is 2.36 mg/kg/day. Another oral study was conducted in Osborne-Mendel rats including two dose groups, however due to insufficient dose spacing and less than one year exposure, the study is considered inferior as it limits characterization of the dose-response relationship and estimation of the TD_{50} (Ref. 18).

Taking into consideration the carcinogenicity data generated by NTP in both mice and rats, the TD_{50} for the most sensitive sex/site from the most appropriate study is 2.33 mg/kg/day. This is the TD_{50} value derived from F344 female rats based on the incidence of nasal cavity tumors (Table 1).

Given that the TD_{50} values recommended for the derivation of an inhalation AI and an oral AI are very similar (2.33 and 2.36 mg/kg/day, respectively), a single AI for both routes of administration is calculated below using a TD_{50} value of 2.3 mg/kg/day.

Calculation of AI

Lifetime AI = TD_{50}/50000 x 50 kg

Lifetime AI = 2.3 mg/kg/day/50000 x 50 kg

Lifetime AI = 2 μg/day

References

1. ATSDR. U.S. Department of Human Health and Services, Agency for Toxic Substances and Disease Registry, Toxicological Profile for 1,2-Dibromoethane, September 2018.

2. EU Council Directive 87/ 1 81 /EEC, amending the Annex to Directive 79/117/EEC prohibiting the placing on market and use of plant protection products containing certain active substances. Official Journal of the European Communities 1987; L 71/33.

3. Moriya M, Ohta T, Watanabe K, Miyazawa T, Kato K, Shirasu, Y. Further: Mutagenicity studies on pesticides in bacterial reversion assay systems. Mutat Res 1983;116:185-216.

4. McCann J, Choi E, Yamasaki E, Ames B. Detection of Carcinogens as Mutagens in the Salmonella/Microsome Test: Assay Of 300 Chemicals. Proc Natl Acad Sci USA 1975;72:5135-5139.

5. Rannug U, Sundvall A and Ramel C. The Mutagenic Effect of 1,2-Dichloroethane on *Salmonella typhimurium* 1. Activation through Conjugation with Glutathione in Vitro. Chem Biol Interact 1978;20:1-16.

6. Strobel K, Grummt T. Aliphatic and Aromatic Halocarbons as Potential Mutagens in Drinking Water. iii. Halogenated Ethanes and Ethenes. Toxicol Environ Chem 1987;15:101-128.

7. Dunkel VC, Zeiger E, Brusick D, Mccoy E, McGregor D, Mortelmans K, Rosenkranz HS, Simmon, VF. Reproducibility of Microbial Mutagenicity Assays: II. Testing of Carcinogens and Noncarcinogens in *Salmonella typhimurium* and Escherichia Coli. Environ Mol Mutagen 1985;7(Suppl. 5):1-248.

8. Clive D, McCuen R, Spector JFS, Piper C, Mavournin KH. Specific Gene Mutations in L5178Y Cells in Culture: A Report of The U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 1983;115:225-251.

9. Smith-Oliver T, Working PK, White RD, Butterworth BE. Induction of DNA repair in rat spermatocytes and hepatocytes by 1,2-dibromoethane: the role of glutathione conjugation. Carcinogenesis 1986;7:467-472.

10. Tan EL, Hsie AW. Mutagenicity and cytotoxicity of haloethanes as studied in the CHO/HGPRT system. Mutation Research 1981;90:183-191.

11. Asita A. A comparative study of the clastogenic activity of ethylating agents. Mutagenesis 1989;4:432-436.

12. Takasawa H, Takashima R, Narumia K, Kawasako K, Hattoria A, Kawabata M, Shuichi Hamada S. Results of the International Validation of the *in vivo* rodent alkaline comet assay for the detection of genotoxic carcinogens: Individual data for 1,2-dibromoethane, p-anisidine, and o-anthranilic acid in the 2nd step of the 4th phase Validation Study under the JaCVAM initiative. Mutat Res 2015;786–788:144–150.

13. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, World Health Organization (WHO). Re-Evaluation of some organic chemicals, hydrazine and hydrogen peroxide. 1999;71:641.

14. Carcinogenicity Potency Database (CPDB). [Online]. Available from: URL: https://files.toxplanet.com/cpdb/index.html

15. Lhasa Carcinogenicity Database. [Online]. Available from: URL: https://carcdb.lhasalimited.org/carcdb-frontend/

16. Van Duuren BL, Melchionne S, Kline SA, Seidman I. Carcinogenicity bioassays of bromoacetaldehyde and bromoethanol- Potential metabolites of dibromoethane. Teratogenesis, Carcinogenesis and Mutagenesis 1985;5:393-403.

17. Van Duuren BL, Melchionne S, Seidman I, Pereira MA. Chronic bioassays of chlorinated humic acids in B6C3F1 mice. Environmental Health Perspectives 1986;69:109-117.

18. National Toxicology Program. Bioassay of 1,2-dibromoethane for possible carcinogenicity (CAS No. 106-93-4). National Toxicology Program Technical Report 1978: TR-86.

19. National Toxicology Program. Carcinogenesis bioassay of 1,2-dibromoethane (CAS No. 106-93-4) in F344 rats and B6C3F1 mice (inhalation study). National Toxicology Program Technical Report 1982: TR-210.

20. Wong LCK, Winston JM, Hong CB, Plotnick H. Carcinogenicity and toxicity of 1,2-dibromoethane in the rat. Toxicology and Applied Pharmacology 1982;63:155-165.

21. Stinson S, Reznik G, Ward J. Characteristics of proliferative lesions in the nasal cavities of mice following chronic inhalation of 1,2-dibromoethane. Cancer Letters 1981;12:121-129.

22. Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. An Adverse Outcome Pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regulatory Toxicology and Pharmacology 2018;96:30-40.

23. Proctor DM, Gatto NM, Hong SJ, Allamneni KP. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicology Science 2007;98:313-26.

Epichlorohydrin (CAS# 106-89-8)

Potential for human exposure

Epichlorohydrin is used in the synthesis of active pharmaceutical ingredients.

Mutagenicity/genotoxicity

The genotoxicity of epichlorohydrin has been reviewed (Ref. 1-3). Epichlorohydrin is mutagenic and genotoxic *in vitro*, with mixed results of genotoxicity tests *in vivo*. While genotoxicity *in vitro* is seen both with and without liver S9 metabolic activation, activity tends to be suppressed by S9 (Ref. 3). Epichlorohydrin is mutagenic in several strains of *Salmonella typhimurium* and in *Escherichia coli WP2 uvrA* with and without metabolic activation using both plate incorporation and preincubation protocols (Ref. 4). *In vitro*, epichlorohydrin is positive in mammalian cells for mutation, and for chromosome and DNA damage.

Carcinogenicity

Epichlorohydrin is classified as a Group 2A carcinogen, probably carcinogenic to humans (Ref. 1). Epichlorohydrin is a site-of contact carcinogen, by oral, subcutaneous and inhalation routes.

In an oral study, Wester et al. (Ref. 5) treated rats by oral gavage with epichlorohydrin, 5 times per week for lifetime at 2 and 10 mg/kg, when converted to an average daily dose for 7 days per week, the doses shown in the CPDB (Ref. 6) are 1.43 and 7.14 mg/kg/d, respectively. In the surviving rats at the end of the study, squamous cell carcinomas were found in the forestomachs of all 24 females and 35 of 43 males at the high dose, and in 2 of 27 females and 6 of 43 males at the low dose. The tumors were considered low grade and there was no evidence of metastasis; no increase in tumors was found at other sites. At both dose levels, there were proliferative changes in the forestomach mucosa, in some cases with ulceration and necrosis at the high dose. A TD_{50} of 2.55 mg/kg/day is reported in the CPDB. The findings are consistent with the squamous cell carcinomas seen in forestomachs of male Wistar rats treated with epichlorohydrin in drinking water for up to 81 weeks (Ref. 7). The Konishi et al. study is not included in the CPDB and not considered in this monograph because of technical deficiencies, and poor condition of the animals.

In an inhalation study, Laskin et al. (Ref. 8) treated male Sprague Dawley rats with epichlorohydrin by inhalation, 6 hours/day, 5 days/week, either for a short-term regimen (30 exposures at 100 ppm) with lifetime observation (140 rats per group), or throughout lifetime at lower doses, 10 and 30 ppm (100 rats per group). After the shorter-term and high dose exposure, squamous cell carcinomas of the nasal cavity in 15/140 rats and respiratory tract papillomas in 3/140 rats were observed associated with severe inflammation in the nasal turbinates, the larynx and the trachea. After lifetime exposure, tumors were seen in 2/100 animals exposed to a dose of 30 ppm and only in the nasal cavity (1 nasal carcinoma and 1 nasal papilloma). Despite the low tumor incidence, a TD_{50} of 421 mg/kg/day is reported in the CPDB.

In a subcutaneous study, Van Duuren et al. (Ref. 9) found sarcomas at the injection site after subcutaneous injection of epichlorohydrin in mice, but no increase in tumor incidence after dermal application, and weekly i.p. injections for over 64 weeks. Storrer et al. (Ref. 10) injected mice (AJ strain) with total doses of 20, 50 or 100 mg/kg epichlorohydrin given three times per week for eight weeks. There was a significant increase in the number of lung tumors in males treated with the highest dose (0.80 ± 0.68, compared with 0.47 ± 0.63 in controls; $p < 0.01$), but not in other groups.

Epichlorohydrin – Details of carcinogenicity studies

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD$_{50}$ (mg/kg/d)
Ref. 5[a]	50/sex Wistar rat	104 weeks, Gavage	50	**1:** 2 and 10 mg/kg	Forestomach; squamous cell carcinomas female	2.55[b,c]
Ref. 8	140 Male Sprague Dawley rat	30 exposures, Inhalation	140	**1:** 100 ppm	Nasal squamous cell Carcinomas	NC[d]
	100 Male Sprague Dawley rat	Lifetime, Inhalation	150	**2:** 10 and 30 ppm	Nasal squamous cell carcinoma	421[b]
Ref. 9	50 Female ICR/Ha Swiss mice	61 weeks, SC	150	**1:** 1 mg/once a week	Injection site sarcomas	NC[e]
Ref. 9	50 Female ICR/Ha Swiss mice	70 weeks, Skin	150	**1:** 2 mg/ 3 times/ week	No skin papillomas or carcinomas	NC[e]
Ref. 9	50 Female ICR/Ha Swiss mice	64 weeks, IP	130	**1:** 5.71 mg/ once a week	No tumors (including no injection site sarcomas)	NC[f]
Ref. 7	18/ group Male Wistar rats	81 weeks, Drinking water	Yes	**3:** 375, 750 and 1500 ppm	Forestomach Squamous cell carcinomas	NC[g]

NC – Not Calculated, SC – Subcutaneous, IP - Intraperitoneal

[a] Carcinogenicity study selected for AI calculation

[b] The TD$_{50}$ values are taken from CPDB (Ref. 6)

[c] The TD$_{50}$ value represents the TD$_{50}$ from the most sensitive tumor site

[d] Not calculated due to short term exposure

[e] Not calculated due to limitations of the study design (injection, single dose level, and did not examine all tissues histologically). The skin painting studies showed no increase in skin papillomas or carcinomas.

[f] Not calculated: Although TD$_{50}$ is listed in CPDB, there was no increase in tumors

[g] Not calculated because the group size was small, the rats were in poor condition, dosing had to be stopped intermittently, and there was body weight loss in all dose groups

Mode of action for carcinogenicity

Epichlorohydrin caused tumors only at the site of contact; forestomach and oral cavity tumors after oral exposure, nasal tumors after inhalation and injection site sarcomas after subcutaneous injection.

Epichlorohydrin is mutagenic *in vitro* in bacteria and mammalian cells (Ref. 4). It is highly irritating to the exposed tissues. For example, dose-related lesions of the forestomach were observed in rats given epichlorohydrin by gavage at 3, 7, 19 and 46 mg/kg/day for 10 days, or 1, 5 and 25 mg/kg/day for 90 days (Ref. 11). There were a range of inflammatory and epithelial alterations; most pronounced were dose-related increase in mucosal hyperplasia and hyperkeratosis. Data indicate that epichlorohydrin is absorbed, and its metabolites enter systemic circulation; however, tumors are seen only at sites of direct contact. For more details on relevance of forestomach tumors see acrylonitrile and benzyl chloride monographs in the ICH M7 Addendum (ICH M7 (R1), 2018).

Regulatory and/or published limits

The World Health Organization (Ref. 12) has published a provisional total daily intake of 0.14 µg/kg/day or 8.4 µg/day (for a 60 kg adult), based on the assumption of a non-linear dose response for this site-of-contact carcinogen. The US EPA used linear extrapolation to derive a drinking water level (1 in 10^5 risk of excess cancer) of 30 µg/L or about 60 µg/day (Ref. 13), using data from Konishi et al. (Ref. 7). US EPA also calculated an inhalation concentration of 8 µg/m^3 for a 1 in 10^5 excess cancer risk, or 230 µg/day, using ICH Q3C assumptions for human daily breathing volume (Ref. 13).

FDA/CFSAN calculated the Unit Cancer Risk of 2.7 x 10^{-3} (mg/kg/day)$^{-1}$ using the data in Konishi et al. cited in the table above (Ref. 14). A food additive contaminant migrating into human food at an exposure of over 0.37 µg/kg or 22 µg/day would result in an estimated cancer risk over 1 in 10^6.

Acceptable intake (AI)

<u>Rationale for selection of study for AI calculation</u>

The oral gavage study of Wester et al. (Ref. 5) is the most robust study for calculation of the AI with the most sensitive species and tissue. The study included appropriate dose range for measuring tumor incidence demonstrating a clear dose response and provides sufficient data for the calculation of a compound specific AI.

Calculation of AI

Lifetime AI = TD_{50}/50,000 x 50 kg

Lifetime AI = 2.55 mg/kg/day/50,000 x 50 kg

Lifetime AI = 3 µg/day

References

1. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1987;71:603-628. Available from: URL: http://monographs.iarc.fr/ENG/Monographs/vol71/mono71-26.pdf

2. Srám RJ, Landa L, et al. Effects of occupational exposure to epichlorohydrin on the frequency of chromosome aberrations in peripheral lymphocytes. Mutat Res 1983;122:59-64.

3. Giri AK. Genetic toxicology of epichlorohydrin: A review. Mutat Res 1977;386:25-38.

4. Canter DA, Zeiger E, et al. Comparative mutagenicity of aliphatic epoxides in *Salmonella*. Mutat Res 1986;172:105-38.

5. Wester PW, van der Heijden CA, et al. Carcinogenicity study with epichlorohydrin (CEP) by gavage in rats. Toxicology 1985;36:325-39.

6. Carcinogenicity Potency Database (CPDB). [Online]. Available from: URL: https://files.toxplanet.com/cpdb/index.html

7. Konishi Y, Kawabata A, et al. Forestomach tumors induced by orally administered epichlorohydrin in male Wistar rats. Gann 1980;71:922-3.

8. Laskin S, Sellakumar AR, et al. Inhalation carcinogenicity study of epichlorohydrin in noninbred Sprague-Dawley rats. J Natl Cancer Inst 1980;65:751-7.

9. Van Duuren BL, Goldschmidt BM, et al. Carcinogenic activity of alkylating agents. J Natl Cancer Inst 1974;53:695-700.

10. Stoner GD, Conran PB, Greisiger EA, Stober J, Morgan M, Pereira MA. Comparison of two routes of chemical administration on the lung adenoma response in strain A/J mice. Toxicol Appl Pharmacol 1986;82:19-31.

11. Daniel FB, Robinson M, et al. Toxicity studies of epichlorohydrin in Sprague-Dawley rats. Drug Chem Toxicol 1996;19:41–58.

12. World Health Organization (WHO). Epichlorohydrin in drinking-water. Background document for development of WHO Guidelines for Drinking-water Quality. 2004; WHO/SDE/WSH/03.04/94.

13. United States Environmental Protection Agency (USEPA). Integrated Risk Information System (IRIS). Epichlorohydrin (CASRN 106-89-8) Cancer Assessment.1988; Available from: URL: https://iris.epa.gov/ChemicalLanding/&substance_nmbr=50

14. United States Food and Drug Administration (USFDA). Indirect food additives: Paper and paperboard components. 1987;52:46744-46747.

Ethyl bromide (CAS# 74-96-4)

Potential for human exposure

Ethyl bromide (bromoethane) is a colorless volatile and flammable liquid. It is an alkylating agent used primarily as a reagent in synthesis of pharmaceuticals. Its close analog, chloroethane, listed in M7, is a mutagenic carcinogen.

Mutagenicity/genotoxicity

Ethyl bromide is mutagenic per the principles of ICH M7 and genotoxic *in vitro*. The mutagenicity of ethyl bromide was evaluated in Salmonella tester strains TA 97, TA 98, TA 100 and TA 104, both in the presence and absence of added metabolic activation by Aroclor-induced rat liver S9 fraction (Ref. 1). Ethyl bromide is a volatile and hydrophobic compound, it was tested in both the standard Salmonella assay and in the same assay modified by incubation in a desiccator. In the standard assay, at concentrations of 5, 10, 50, 100, 500, and 1000 μg/plate ethyl bromide was not mutagenic. However, ethyl bromide was mutagenic in bacterial reverse mutation assays in *Salmonella typhimurium* TA98, TA100, TA104 with metabolic activation and mutagenic in TA 97 with and without metabolic activation. TA100, TA1535 and *Escherichia coli* WP2 with and without metabolic activation when tested as a gas in sealed desiccators (Ref. 2, 3).

In cultured CHO cells, ethyl bromide induced sister chromatid exchanges (SCEs) but not chromosomal aberrations in both the presence and absence of exogenous metabolic activation (Ref. 4).

Carcinogenicity

The IARC has determined that ethyl bromide is not classifiable as to its carcinogenicity to humans (Ref. 5). There is no epidemiological data relevant to carcinogenicity and limited evidence in experimental animals for the carcinogenicity of ethyl bromide.

In animals, evidence of carcinogenicity was identified from a 2-year bioassay from the National Toxicology Program (NTP) that evaluated the inhalation route of ethyl bromide administration in rats and mice. A variety of effects (dependent on species and sex) were seen with exposures of 100, 200, or 400 ppm 6 hours/day, 5 days/week (Ref. 3).

There was some evidence of carcinogenic activity of ethyl bromide for male F344/N rats, as indicated by increased incidences of pheochromocytomas and malignant pheochromocytomas, combined, of the adrenal medulla (control, 8/40; 100 ppm, 23/45; 200 ppm, 18/46; 400 ppm, 21/46). In female rats, the incidences of gliomas in the brain and adenomas in the lung were increased However, the incidence of the former was within historical control and the latter the incidence was not statistically significant by trend test or pairwise comparisons. For male B6C3F1 mice, there was equivocal but statistically significant increase in incidences of neoplasms of the lung (alveolar/bronchiolar adenomas or carcinomas). There was clear evidence of carcinogenic activity for female B6C3F1 mice, as indicated by neoplasms of the uterus (adenomas or adenocarcinomas).

Ethyl Bromide – Details of carcinogenicity studies

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses*	Most sensitive tumor site/type/sex	TD$_{50}$ (mg/kg/d)
Ref. 3	50/sex/ group B6C3F1 mice	105 weeks, Inhalation	50	**3:** 100, 200, 400 ppm M: 115, 229, 458 F: 137, 275, 550 mg/kg/d	Uterus / Female	535^
Ref. 3	50/sex/ group F344/N Rats	106 weeks, Inhalation	50	**3:** 100, 200, 400 ppm M: 22.9, 45.8, 91.7 F: 32.7, 65.5, 131 mg/kg/d	Adrenal / Male	149^
Ref. 3	50/sex/ group F344/N Rats	106 weeks, Inhalation	50	**3:** 100, 200, 400 ppm M: 22.9, 45.8, 91.7 F: 32.7, 65.5, 131 mg/kg/d	Liver	670^

* mg/kg/d values stated in CPDB (Ref. 6) and calculated by method used to standardize average daily dose levels from variety of routes of administration, dosing schedules, species, strains and sexes; values stated in CPDB accounted for exposure duration of 24 h per day for 7 days per week. (Dose rate = (administered dose × intake/day × number of doses/week) / (animal weight × 7 days/week))
^ TD$_{50}$ calculated in CPDB

Mode of action for carcinogenicity

Ethyl bromide is an alkylating agent. It is a mutagenic carcinogen, and the acceptable intake is calculated by linear extrapolation from the TD$_{50}$.

Regulatory and/or published limits

For ethyl bromide, the ACGIH threshold limit value-time-weighted average (TLV-TWA) for ethyl bromide is 5 ppm (22 mg/m^3), while OSHA and NIOSH indicate the TWA as 200 ppm (890 mg/m^3) (Ref. 7). The ACGIH estimates this value with a notation for skin absorption, but OSHA and NIOSH estimates are based on inhalation studies.

Acceptable intake (AI)

Rationale for selection of study for AI calculation

Ethyl bromide is a mutagenic carcinogen via the inhalation route of exposure. Although no information on the inhaled bioavailability of ethyl bromide was found, organic solvents have high inhalation bioavailability values (Ref. 8) and systemic exposure via inhalation route has been demonstrated in multiple studies by clinical observations (Ref. 9). Neoplastic lesions were observed in multiple organs where systemic exposure is indicated in mice and rats in addition to

the site-of-contact tissues (e.g., lung). Therefore, it is reasonable to apply the AI derived from inhalation studies for other routes of administration.

Considering all the available data from the inhalation studies in rats and mice, the most sensitive tumor endpoint was the combined pheochromocytoma and malignant pheochromocytomas of the adrenal gland in male F344/N rats. The TD_{50} calculated by CPDB for this endpoint was, however, not statistically significant. This is due to the lack of a significant dose response trend test for the endpoint. However, calculating a TD_{50} for each dose separately results in statistically significant TD_{50} values for each dose (TD_{50} = 32.2 mg/kg/d for low dose, 115 mg/kg/d for mid dose, 162 mg/kg/d for high dose – Note 2). Therefore, the effect is considered relevant and the lowest TD_{50} value of 32.2 mg/kg/d is used as it was considered to conservatively yield the most sensitive potency estimate for calculating the AI.

Calculation of AI

Lifetime AI = TD_{50}/50,000 x 50 kg

Lifetime AI = 32.2 mg/kg/day/50,000 x 50 kg

Lifetime AI = 32 μg/day

References

1. Strubel K, Grummt T. Aliphatic and aromatic halocarbons as potential mutagens in drinking water. III. Halogenated ethanes and ethenes. Toxicology and Environmental Chemistry 1987;15:101–128.

2. Patty's Industrial Hygiene and Toxicology: Volume 2A, 2B, 2C: Toxicology. New York. John Wiley 1981;3484.

3. NTP. Toxicology and Carcinogenesis Studies of Bromoethane (EthylBromide) (CAS NO. 74-96-4) in F344/N Rats and B6C3F Mice (Inhalation Studies). National Toxicology Program, US Dept Health and Human Services. 1989; NTP-TR 363.

4. Loveday KS, Lugo MH, Resnick MA, Anderson BE, Zeiger E. Chromosome aberration and sister chromatid exchange tests in vitro in Chinese hamster ovary cells in vitro: II. Results with 20 chemicals. Environ. Molec Mutagen 1989;13:60-94.

5. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1999;71:1305-1307.

6. Carcinogenicity Potency Database (CPDB). [Online]. Available from: URL: https://files.toxplanet.com/cpdb/index.html

7. NIOSH. The National Institute for Occupational Safety and Health (NIOSH) Publications & Products. Available from: URL: https://www.cdc.gov/niosh/idlh/74964.html

8. Fiserova-Bergerova, V. Toxicokinetics of organic solvents. Scand J Work Environ Health 1985;11:suppl 1, 7-21.

9. Sayers RR, Yant WP, Thomas BGH, Berger LB. Physiological response attending exposure to vapors of methyl bromide, methyl chloride, ethyl bromide and ethyl chloride. Public Health Bull 1929;185:1-56.

Formaldehyde (CAS# 50-00-0)

Potential for human exposure

Formaldehyde exposure occurs in air, water, and food, and is a common endogenous component of biological materials and is a naturally occurring component of many foods such as meat, dairy products, fruit and vegetables. Levels of daily exposure to formaldehyde via the dietary route have been estimated in the range of 1.5-14 mg/day (Ref. 1-3). Formaldehyde is also a product of normal human metabolism and is essential for the biosynthesis of certain amino acids. The human body produces and uses approximately 50 g of formaldehyde per day, which is rapidly metabolized and cleared from blood plasma (Ref. 3-5). Formaldehyde is used in the synthesis and formulation of pharmaceuticals. In some cases, formaldehyde can function as the active ingredient in a drug. Formaldehyde is also found as a component of some consumer products and can be produced during cooking or smoking.

Mutagenicity/genotoxicity

Formaldehyde is a mutagenic compound (Ref. 6). Formaldehyde induced mutations in the bacterial reverse mutation assay with and without S9 activation. It induced deletions, point mutations, insertions, and cell transformations in mammalian cells (Ref. 7). Formaldehyde is also clastogenic causing chromosomal aberrations, micronuclei, and sister chromatid exchanges in rodent and human primary cell lines. *In vivo* studies have also detected genotoxic effects primarily at the site of contact (Ref. 8).

Carcinogenicity

IARC considers formaldehyde to be a Group 1 carcinogen, or carcinogenic in humans based on cancer of the nasopharynx and leukemia (Ref. 6). There are several oral and inhalation animal studies (summarized in Table 1) conducted with formaldehyde. The carcinogenicity of formaldehyde is specific to inhalation and formaldehyde is not carcinogenic via the oral route (Ref. 6, 9-11).

Formaldehyde was negative in oral carcinogenicity studies in rodents. In carcinogenicity studies conducted by the inhalation route, tumors in the nasal cavity have been observed in rodents.

The nasal tumors observed following inhalation of formaldehyde were attributed to continuous cycles of tissue degeneration and regeneration (cytolethality/regenerative cellular proliferation; CRCP) rather than to a direct genotoxic effect (Ref. 12). Formation of DNA-protein crosslinks is probably involved in the cytolethality. Predicted additional cancer risks for an 80-year continuous environmental exposure to formaldehyde was modeled using CRCP. The risk predictions were obtained from what Conolly et al. (Ref. 12) expected to be significant overestimates of real-world exposures to formaldehyde.

Both IARC and US EPA concluded formaldehyde causes leukemia, in agreement with the conclusion of the NTP 14th Report on carcinogens that formaldehyde causes nasopharyngeal cancer and myeloid leukemia (ML), (Ref. 13). The conclusion that formaldehyde causes cancer was peer reviewed by the National Academy of Science (Ref. 14). The reviews acknowledged that hazard identification for formaldehyde was not straightforward, especially with respect to possible leukemogenicity, in part due to its endogenous production and high reactivity. The most useful studies on the risk of formaldehyde causing ML are the large cohort studies of chemical workers and embalmers (Ref. 15).   The conclusion was that there is a causal association between

800 formaldehyde exposure and mortality from ML (Ref. 16). Albertini and Kaden (Ref. 17)
801 concluded that overall, the available literature on genetic changes following formaldehyde
802 exposure did not provide convincing evidence that exogenous exposure, and specifically exposure
803 by inhalation, induces mutations as a direct DNA-reactive effect at sites distant from the portal-of-
804 entry tissue. This would include proposed mode of actions that involve a stem cell effect at the
805 port of entry with circulation back to the bone marrow. Such exposures have not been shown to
806 induce mutations in the bone marrow or in any other tissues beyond the point of contact.
807
808 Since 2010, two short-term carcinogenicity studies have been conducted and published by the NTP
809 in strains of genetically predisposed mice (male C3B6·129F1-Trp53tm1Brdp53 haplo-insufficient
810 mice and male B6.129-Trp53tm1Brd) (Ref. 18). These short-term carcinogenicity studies were
811 conducted to test the hypothesis that formaldehyde inhalation would result in an increased
812 incidence and/or shortened latency to nasal and lymphohematopoietic tumors and to investigate
813 hypotheses that formaldehyde may induce leukemia by a mechanism not involving DNA adduct
814 formation. This proposed mechanism assumes that inhaled formaldehyde could cause significant
815 genetic damage to stem cells in the nasal epithelium or circulating in local blood vessels. These
816 damaged stem cells could reach the general circulation, undergo lodgment and become leukemic
817 stem cells. The animals were exposed to 7.5 or 15 ppm formaldehyde 6 hours/day, 5 days/week,
818 for 8 weeks and mice were monitored for approximately 32 weeks. At the highest concentrations,
819 significant cell proliferation and squamous metaplasia of the nasal epithelium were observed;
820 however, no nasal tumors were observed. No cases of leukemia were seen in either strain and a
821 low incidence of lymphoma in exposed mice was not considered related to exposure. In addition,
822 no significant changes in hematological parameters were noted. Under the conditions of these
823 studies, the authors concluded that formaldehyde inhalation did not cause leukemia in these strains
824 of genetically predisposed mice (Ref. 18).
825
826 Moreover, multiple studies in rats (Ref. 19-21) and monkeys (Ref. 21, 22) conducted with sensitive
827 analytical methods that can measure endogenous versus exogenous formaldehyde DNA or protein
828 adducts have demonstrated that inhaled exogenous formaldehyde is not systemically absorbed or
829 reaches sites distant from the point of initial contact. In addition to these studies, the available data
830 on the toxicokinetics of formaldehyde suggest that no significant amount of "free" formaldehyde
831 would be transported beyond the portal of entry.
832

833 **Formaldehyde – Details of carcinogenicity studies**

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD$_{50}$ (mg/kg/d)
Ref. 23	42-60/ group C3H Mouse	35- or 64- weeks, Inhalation	59	**3:** 50, 100, 200 mg/m^3	No tumors	NC
Ref. 24	120/sex / group B6C3F1 Mouse	2 years, Inhalation	120	**3:** 2, 5.6, 14.3 ppm	Nasal Turbinates/ Male	43.9[a]
Ref. 24	120/sex/ group F344 Rat	2 years, Inhalation	120	**3:** 2, 5.6, 14.3 ppm	Nasal Turbinates/ Male	0.798[a]
Ref. 25	100/ group	Lifetime, Inhalation	99	**1:** 14.8 ppm	Nasal Mucosa / Male	1.82[a]

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD_{50} (mg/kg/d)
	Male Sprague Dawley Rat					
Ref. 26	45/group Male Wistar Rat	4, 8 or 13 weeks, Inhalation	134	**2:** 10, 20 ppm	Nasal Cavity / Male	NC[b]
Ref. 27	30/group (Undamaged) Male Wistar Rat	3- or 28-months, Inhalation	30	**4:** 0, 0.1, 1.0, 10 ppm	No Tumors for Undamaged animals[c]	NC
Ref. 28	15-16/ group Female Sprague Dawley Rat	24 months, Inhalation	16	**1:** 12.4 ppm	No Tumors	NC
Ref. 29	90 or 147/ group Male F344 Rat	24 months, Inhalation	90	**5:** 0.7, 2, 6, 10, 15 ppm	Nasal Cavity / Male	0.48[a]
Ref. 30	32/ group Male F344 Rat	28 months, Inhalation	32	**3:** 0.3, 2, 15 ppm	Nasal Cavity / Male	0.98[a]
Ref. 31	88/ group Male Syrian Golden Hamster	Lifetime, Inhalation	132	**1:** 10 ppm	No Tumors	NC
Ref. 32	70/sex/ group Wistar Rat	2 years, Drinking water	70	**3:** 1.2, 15, 82 mg/kg/d (M), 1.8, 21, 109 mg/kg/d (F)	No Tumors	NC
Ref. 33	50/sex/ group Sprague Dawley Rat	Lifetime, Drinking water	50	**7:** 10, 50, 100, 500, 1000, 1500, 2500 ppm (0.7, 3.5, 7, 35, 71, 106 176 mg/kg/d[d])	Lymphoblastic leukemia-lymphosarcoma / Male[e]	424[a]

Study	Animals/dose group	Duration/Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD$_{50}$ (mg/kg/d)
Ref. 34	20/sex/group Wistar Rat	24 months, Drinking water	20	**3:** 10, 50, 300 mg/kg/d	No Tumors	NC

834 NC – Not Calculated
835 [a] TD$_{50}$ taken from the CPDB (Ref. 35)
836 [b] Not calculated given the limited duration of dosing
837 [c] After 28 months of exposure animals damaged by electrocoagulation experienced an increase in nasal
838 cavity tumors
839 [d] Calculated based on ICH Q3C assumptions for respiratory parameters
840 [e] There were concerns about study design (pooling of lymphomas and leukemias diagnosed, lack of
841 reporting of non-neoplastic lesions and historical control data, discrepancies of data between this study
842 and Sofritti (Ref. 36) [second report of this study], and lack of statistical analysis) (Ref. 6, 11, 37).
843

844 **Mode of action for carcinogenicity**

845 Formaldehyde was carcinogenic only in studies conducted by the inhalation route in rodents.
846 Tumors in the nasal cavity have been observed and are considered a site of contact effect in
847 rodents. The nasal tumors observed following inhalation of formaldehyde were attributed to
848 continuous cycles of tissue degeneration and regeneration (cytolethality/regenerative cellular
849 proliferation; CRCP) rather than to a direct genotoxic effect. Formation of DNA-protein
850 crosslinks (DPX) is probably involved in the cytolethality of formaldehyde but not considered as
851 the driving mechanism to carcinogenicity. In a recent review of the mode of action of
852 formaldehyde and relevance of rat nasal tumors to humans, the role of cytotoxicity and
853 regenerative cell proliferation was reaffirmed. The authors also indicate that although DNA-
854 protein crosslinks are a good biomarker of exposure, they may not meaningfully contribute to
855 cancer via genotoxic effects except at concentrations that result in tissues levels well above
856 endogenous levels (Ref. 38).
857

858 **Regulatory and/or published limits**
859 For oral exposure to the general population, the ATSDR, Health Canada, International Programme
860 on Chemical Safety (IPCS), and US EPA limit for formaldehyde is 0.2 mg/kg/day or 10 mg/day
861 for a 50 kg person, which is based on a non-cancer endpoint (reduced weight gain and histological
862 changes to the gastrointestinal tract and kidney) (Ref. 39-41). No oral carcinogenicity risk
863 estimates have been performed with formaldehyde, since carcinogenicity is specific to the
864 inhalation route of exposure.
865

866 Occupational limits have been set for air at work places by NIOSH (REL TWA 0.016 ppm),
867 ACGIH (TWA 0.1 ppm), DFG MAKs (TWA 0.3 ppm), and OSHA (PEL TWA 0.75 ppm).
868

869 For inhalation exposure to the general population, the US EPA, IPCS, and Health Canada have
870 developed inhalation cancer risk values (Ref. 11, 40, 41). The US EPA limit is based on a linear
871 cancer model, and Health Canada/IPCS developed nonlinear and linear cancer models. Using the
872 linear method from all three agencies, a daily inhaled dose of 16-32 µg/day would result in a 1 in
873 10^5 excess risk of cancer. However, more recent scientific analysis supports the use of the Health
874 Canada/IPCS nonlinear model, which incorporates mechanistic data (Ref. 42-44). Conolly et al.
875 (Ref. 12) developed a nonlinear / linear mechanistic-based model using empirical rodent and
876 human data for the two modes of action with formaldehyde tumorigenicity: CRCP and DNA-
877 protein cross-links (DPX).

878 Acceptable intake (AI) for inhalation exposure

879 Rationale for selection of study for AI calculation

880

881 The AI for inhalation is based on the carcinogenicity model developed by Conolly et al. (Ref. 12).
882 Figure 1 represents the dose-response hockey stick-shaped model developed by Conolly et al.,
883 (Ref. 12) for a mixed population of smokers and non-smokers. The rat dose response for
884 CRCP/DPX was used by Connolly for the human model in absence of an alternative model. Since
885 the exposure related tumor risk predicted by clonal growth models was extremely sensitive to cell
886 kinetics, Conolly et al. decided to evaluate human cancer risk associated with formaldehyde
887 exposure using both the raw J-shaped dose-response and a hockey stick–shaped transformation of
888 the rat data. This model incorporates the non-linear-based mechanism at the high dose region
889 (CRCP) and the linear mechanism at the low dose region (DPX). As noted above, the translation
890 of DPX into mutations and an assumed linear-dose response emerging from such mutations is not
891 established experimentally. Moreover, experimental results suggest that DPX are not leading to
892 mutations in a linear fashion. Thus, the linear dose-response model at low doses reflect a
893 conservative and practical approach and is not dictated by experimental data.

894

895
896
897 Figure 1. Dose-response model hockey stick-shaped model from (Ref. 12) representing mixed smokers and non-
898 smokers. The dose (mg/day) was based on converting air concentration (ppm) to daily dose using ICH Q3C
899 assumptions for human breathing volume (28,800 L/day).

900

901

902

903

Calculation of inhalation AI

The linear low dose region of Figure 1 was used to determine the dose at a 1 in 100,000 excess cancer risk. Linear regression at the low dose region, which is $\leq$ 24.74 mg/day (converted from 0.7 ppm) results in an equation of $y = 1.62E\text{-}06x - 3.27E\text{-}06$. The dose of 24.74 mg/day was the point at which there is a predicted upward inflection of additional risk. Solving for a 1 in 100,000 excess cancer risk in the regression line (y) results in an acceptable intake of 8.2 mg/day (see Figure 1 dose equivalent to the 1:100,000 risk).

Risk (y) = $1.62E\text{-}06x(\text{dose}) - 3.27E\text{-}06$
$0.00001 = 1.62E\text{-}06x - 3.27E\text{-}06$
$x = (0.00001 + 3.27E\text{-}06) / 1.62E\text{-}06$
Dose (x) = 8.2 mg/day

Lifetime AI (inhalation) = 8 mg/day or 215 ppb, whichever is lower

*Formaldehyde is considered a mutagenic carcinogen by the inhalation route of exposure. The acceptable intake of 8 mg/day represents an upper limit over a 24 hour time period. As described in the introduction section of Appendix 3 of this guideline, "other considerations" may affect final product specifications. WHO recommends a limit of 77 ppb in air as a 30 min average and Health Canada recommends a short-term exposure limit of 100 ppb based as a 1 hour average. These recommended values provide at least a 10-fold margin of exposure to the lowest level at which symptoms were observed. To protect patients from the local irritation and sensitization effects of formaldehyde by the inhalation route of exposure, a lower concentration-based limit of 215 ppb is recommended [8 mg/day over 24 hours of exposure is equal to a concentration limit of 215 ppb (0.008 g/day / 28.8 m^3/day) * 1 / 1293 g/m^3)].

human breathing volume/d - 28.8 m^3
air mass/m3 at standard conditions - 1293 g

Permissible Daily Exposure (PDE) for all other routes

See the introduction to Appendix 3, for information on formaldehyde exposure from the environment.

PDE (all other routes) = 10 mg/day

References

1. Organization for Economic Co-operation and Development (OECD). SIDS Initial Assessment Report. Formaldehyde. 2002.

2. Owen BA, Dudney CS, et al. Formaldehyde in drinking water: Comparative hazard evaluation and an approach to regulation. Regul Toxicol Pharmacol 1990;11:220-36.

3. Dhareshwar SS, Stella VJ. Your prodrug releases formaldehyde: Should you be concerned? No! J Pharm Sci 2008;97:4184–93.

4. Feron VJ, Bruyntjes JP, et al. Nasal tumors in rats after short-term exposure to a cytotoxic concentration of formaldehyde. Cancer Lett 1988;39:101-11.

5. Heck HD, Casanova-Schmitz M, et al. Formaldehyde (CH_2O) concentrations in the blood of humans and Fischer-344 rats exposed to CH_2O under controlled conditions. Am Ind Hyg Assoc J 1985;46:1-3.

6. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Chemical agents and related occupations. Volume 100 F. 2012.

7. Ma TH, Harris MM. Review of the genotoxicity of formaldehyde. Mutat Res 1988;196:37-59.

8. Arts JH, Rennen MA, de Heer C. Inhaled formaldehyde: evaluation of sensory irritation in relation to carcinogenicity. Regul Toxicol Pharmacol 2006;44:144-60.

9. World Health Organization (WHO). Background document for development of WHO guidelines for drinking-water quality. 2005; WHO/SDE/WSH/05.08/48.

10. Scheuplein, RJ. Formaldehyde: The Food and Drug Administration's perspective. Chapter 16. in: Turoski, V (Ed.), Formaldehyde: Analytical Chemistry and Toxicology. American Chemical Society, Washington DC. 1985;210:237-45.

11. International Programme on Chemical Safety (IPCS) Concise International Chemical Assessment Document 40. Formaldehyde. 2002.

12. Conolly RB, Kimbell JS, et al. Human respiratory tract cancer risks of inhaled formaldehyde: dose-response predictions derived from biologically-motivated computational modeling of a combined rodent and human dataset. Toxicol Sci 2004;82:279-96.

13. National Toxicology Program. 2016. Formaldehyde CAS No. 50-00-0. Report on Carcinogens, Fourteenth Edition.; Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service.

14. National Research Council. 2011. Review of the Environmental Protection Agency's Draft IRIS Assessment of Formaldehyde. Washington, DC: The National Academies Press, ISBN 978-0-309-21193-2.

15. Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries. Journal of the National Cancer Institute 2003;95:1615–1623.

16. Hauptmann M, Stewart PA, Lubin JH, et al. Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. Journal of the National Cancer Institute 2009;101:1696–1708.

17. Albertini RJ, Kaden DA. Do chromosome changes in blood cells implicate formaldehyde as a leukemogen? Crit Rev Toxicol 2017;47:145-184.

18. Morgan DL, Dixon D, King DH, Travlos GS, Herbert RA, French JE, Tokar EJ, Waalkes MP, Jokinen MP. NTP Research Report on Absence of Formaldehyde-Induced Neoplasia in Trp53 Haploinsufficient Mice Exposed by Inhalation: Research Report 3. Durham (NC): National Toxicology Program; 2017. PMID: 30016014

987   19. Lu K, Gul H, Upton PB, Moeller BC, Swenberg JA. Formation of hydroxymethyl DNA
988   adducts in rats orally exposed to stable isotope labeled methanol. Toxicol Sci 2012;126:28-
989   38.

990   20. Edrissi B, Taghizadeh K, Moeller BC, Kracko D, Doyle-Eisele M, Swenberg JA, Dedon PC.
991   Dosimetry of N^6-formyllysine adducts following [$^{13}C^2H_2$]-formaldehyde exposures in rats.
992   Chem Res Toxicol 2013;26:1421-3

993   21. Yu R, Lai Y, Hartwell HJ, Moeller BC, Doyle-Eisele M, Kracko D, Bodnar WM, Starr TB,
994   Swenberg JA. Formation, Accumulation, and Hydrolysis of Endogenous and Exogenous
995   Formaldehyde-Induced DNA Damage. Toxicol Sci 2015;146:170-82.

996   22. Moeller BC, Lu K, Doyle-Eisele M, McDonald J, Gigliotti A, Swenberg JA. Determination
997   of N2-hydroxymethyl-dG adducts in the nasal epithelium and bone marrow of nonhuman
998   primates following 13CD2-formaldehyde inhalation exposure. Chem Res Toxicol
999   2011;24:162-4.

1000   23. Horton AW, Tye R, et al. Experimental carcinogenesis of the lung. Inhalation of gaseous
1001   formaldehyde or an aerosol of coal tar by C3H mice. J Natl Cancer Inst 1963;30:31-43.

1002   24. Kerns WD, Pavkov KL, et al. Carcinogenicity of formaldehyde in rats and mice after long-
1003   term inhalation exposure. Cancer Res 1983;43:4382-92.

1004   25. Sellakumar AR, Snyder CA, et al. Carcinogenicity of formaldehyde and hydrogen chloride in
1005   rats. Toxicol Appl Pharmacol 1985;81:401-6.

1006   26. Feron VJ, Bruyntjes JP, Woutersen RA, Immel HR, Appelman LM. Nasal tumours in rats
1007   after short-term exposure to a cytotoxic concentration of formaldehyde. Cancer Lett
1008   1988;39:101-11.

1009   27. Woutersen RA, van Garderen-Hoetmer A, et al. Nasal tumours in rats after severe injury to
1010   the nasal mucosa and prolonged exposure to 10 ppm formaldehyde. J Appl Toxicol
1011   1989;9:39-46.

1012   28. Holmström M, Wilhelmsson B, et al. Histological changes in the nasal mucosa in rats after
1013   long-term exposure to formaldehyde and wood dust. Acta Otolaryngologica 1989;108:274-
1014   83.

1015   29. Monticello TM, Swenberg JA, et al. Correlation of regional and nonlinear formaldehyde-
1016   induced nasal cancer with proliferating populations of cells. Cancer Res 1996;56:1012-22.

1017   30. Kamata E, Nakadate M, et al. Results of a 28-month chronic inhalation toxicity study of
1018   formaldehyde in male Fisher-344 rats. J Toxicol Sci 1997;22:239-54.

1019   31. Dalbey WE. Formaldehyde and tumors in hamster respiratory tract. Toxicology 1982;24:9-
1020   14.

1021   32. Til HP, Woutersen R, et al. Two-year drinking-water study of formaldehyde in rats. Food
1022   Chem Toxicol 1989;27:77-87.

1023   33. Soffritti M, Maltoni C, et al. Formaldehyde: an experimental multipotential carcinogen.
1024   Toxicol Ind Health 1989;5:699-730.

1025 34. Tobe M, Naito K, et al. Chronic toxicity study on formaldehyde administered orally to rats.
1026   Toxicology 1989;56:79-86.

1027 35. Carcinogenicity Potency Database (CPDB). [Online]. Available from: URL:
1028   https://files.toxplanet.com/cpdb/index.html

1029 36. Soffritti M, Belpoggi F, et al. Results of long-term experimental studies on the
1030   carcinogenicity of formaldehyde and acetaldehyde in rats. Ann N Y Acad Sci 2002;982:87–
1031   105.

1032 37. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.
1033   Formaldehyde, 2-butoxyethanol and 1-tertbutoxypropan- 2-ol. 2006;88:1–478.

1034 38. Thompson CM, Gentry R, Fitch S, Lu K, Clewell HJ. An updated mode of action and human
1035   relevance framework evaluation for Formaldehyde-Related nasal tumors, Critical Reviews in
1036   Toxicology 2020;50:919-952.

1037 39. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for
1038   Formaldehyde. U.S. Department of Health and Human Services, Public Health Service.
1039   1999; Available from: URL: http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=220&tid=39

1040 40. Health Canada. Priority substances list assessment report: Formaldehyde. Ottawa. Ministry of
1041   Public Works and Government Services. 2001; Available from: URL: http://www.hc-
1042   sc.gc.ca/ewh-semt/pubs/contaminants/psl2-lsp2/index_e.html

1043 41. United States Environmental Protection Agency (USEPA). Integrated Risk Information
1044   System (IRIS). Formaldehyde (CASRN 50-00-0). 1990.

1045 42. Conolly RB, Kimbell JS, et al. Biologically motivated computational modeling of
1046   formaldehyde carcinogenicity in the F344 rat. Toxicol Sci 2003;75:432-47.

1047 43. Starr TB, Swenberg JA. A novel bottom-up approach to bounding low-dose human cancer
1048   risks from chemical exposures. Regul Toxicol Pharmacol 2013;65:311-5.

1049 44. Swenberg JA, Moeller BC, et al. Formaldehyde carcinogenicity research: 30 years and
1050   counting for mode of action, epidemiology, and cancer risk assessment. Toxicol Pathol
1051   2013;41:181-9.

1052

Styrene (CAS# 100-42-5)

Potential for human exposure

Styrene exposure to the general population occurs via environmental contamination and dietary exposure (Ref. 1). In the general population, indoor and outdoor air account for the largest exposures. However, smoking one pack of cigarettes would likely lead to the inhalation of milligram quantities of styrene (Ref. 2). Styrene has been detected as a natural constituent of a variety of foods and beverages, the highest levels occurring in cinnamon. Polystyrene and its copolymers are widely used as food-packaging materials and monomers such as styrene can migrate to food at low levels. The daily intake of styrene from dietary sources has been estimated to be 1-4 µg in the United Kingdom, 2-12 µg in Germany and 9 µg in the United States (Ref. 3, 4). Styrene is used in the synthesis of active pharmaceutical ingredients.

Mutagenicity/genotoxicity

Styrene has produced contradictory findings in the *in vitro* bacterial reverse mutation assay and it is predominantly inactive in the *in vivo* chromosome aberration, micronucleus and UDS assays when conducted according to OECD guidelines. Inconsistent results in the bacterial reverse mutation (Ames) test were attributed to styrene volatility, poor solubility, and different metabolic systems (Ref. 5). Styrene was positive for mutagenicity in the Ames test only with metabolic activation (Ref. 5), where it is converted to electrophilic intermediates (e.g., styrene 7, 8-oxide) to enable formation of covalent adducts with DNA. The main metabolite of styrene is styrene 7, 8-oxide. Most the genetic damage associated with styrene exposure is thought to be due to styrene 7, 8-oxide, which is further detoxified to styrene glycol. Styrene exposure elevated DNA adducts (N^7-guanine, O^6-guanine, and N^1-adenine) and SCEs in both animal models and in humans, and DNA strand breaks in humans (Ref. 5, 6). In a critical review of styrene genotoxicity based on the requirements outlined in the current OECD guidelines, Moore et al. (Ref. 7) concluded that it is unclear whether unmetabolized styrene is mutagenic in the Ames test, while the styrene 7, 8-oxide metabolite is clearly mutagenic. The authors also noted that most styrene 7, 8-oxide Ames positive data was collected without using exogenous metabolic activation, meaning that styrene 7, 8-oxide was not further metabolized to styrene glycol.

Styrene was mutagenic in glycophorin A (GPA) variant frequencies in erythrocytes from 28 workers inhalation-exposed to ≥ 85 mg/m^3 styrene (Ref. 8). Lymphocytes from styrene exposed workers had increased mutation frequencies (MFs) at the *HPRT* locus (Ref. 9).

Two *in vitro* mammalian gene mutation studies were identified. In the hypoxanthine-guanine phosphoribosyl transferase (*Hprt*) assay, styrene induced only small increases in *HPRT* MFs in V79 cells (Ref. 10). Similarly, in V79 cells, styrene induced small increases in *Hprt* MFs with large variability observed in a liver perfusion system and little to no increases with or without S9 (Ref. 11). No rodent *in vivo* mutation studies evaluating styrene or styrene 7, 8-oxide were identified.

Based on standard regulatory tests, there is no convincing evidence that styrene possesses significant genotoxic potential *in vivo* from the available data in experimental animals. However, genotoxicity associated with styrene exposure (related to formation of styrene 7, 8-oxide) has been proposed as a possible mode of action for styrene-induced carcinogenicity in experimental animals and humans (Ref. 1).

Carcinogenicity

The IARC has classified styrene and the metabolite styrene 7, 8-oxide in Group 2A, "probably carcinogenic to humans based on limited evidence in humans and sufficient evidence in experimental animals" (Ref. 5). Styrene is also reasonably anticipated to be a human carcinogen by the NIH (Ref. 1). Possible modes of action for styrene-induced carcinogenicity involve genotoxic and cytotoxic effects together with immunosuppression (Ref. 1). NTP listed styrene as "reasonably anticipated to be a human carcinogen" in its 12th and 14th Reports on Carcinogens (Ref. 12, 13). The NRC concluded "reasonably anticipated to be a human carcinogen" was an appropriate carcinogenicity classification for styrene, due to limited carcinogenicity evidence in humans, sufficient evidence in animal studies, and other mechanistic data supporting carcinogenicity (Ref. 6).

A recent systematic review of epidemiologic studies of exposure to styrene concluded that besides some limitations of available research such as lack of quantitative estimates of styrene, the risk of specific cancers found no strong and consistent evidence of a causal association between styrene and Non-Hodgkin lymphoma and its subtypes, all leukemia, subtypes of leukemia or cancers of the esophagus, pancreas, lung, kidney or other sites (Ref. 14).

In the CPDB, styrene is reported to be carcinogenic in mice via the oral and inhalation routes and rats via the inhalation route (Ref. 15). The National Institutes of Health Report on Carcinogens (Ref. 1) considered the most robust studies to be the two-year studies via (1) oral exposure in B6C3F1 mice and (2) inhalation exposure in CD-1 mice. In male B6C3F1 mice, oral exposure to styrene increased the combined incidence of alveolar and bronchiolar adenomas and carcinomas (Ref. 16). In the inhalation study, in male and female CD-1 mice, there was an increase in the incidence of pulmonary adenomas and also an increase in pulmonary carcinomas in females in the high-dose group (Ref. 17).

IARC evaluated nine studies each (with various routes of application) in mice and rats for styrene and three each in mice and rats for styrene-7,8-oxide. For styrene in mice in one study with transplacental exposure followed by gavage using O20 mice, an increase of lung carcinoma and adenoma was observed in pups whereas a second study in C57BL mice was negative (Ref. 18). Two out of five studies with inhalation in mice reported an increase in lung bronchoalveolar tumors in CD-1 mice (Ref. 16, 19) whereas the other three (in C57BL/6 mice) were negative (Ref. 19). One study with oral application found increased lung tumors and a positive trend for hepatocellular carcinoma (Ref. 16). One study with i.p. application gave negative results (Ref. 20). In two studies in SD-rats with inhalation exposure, styrene increased mammary gland tumors (Ref. 21, 22), whereas four oral studies, three with gavage (Ref. 17, 22) and one via drinking water (Ref. 23), were negative as well as one study with transplacental exposure followed by gavage (Ref. 17), one study with i.p. application and one with s.c. application (Ref. 22). Styrene-7-8-oxide was tested in three studies in mice, one by gavage (Ref. 24) and two by skin application (Ref. 25, 26). In the oral study by gavage styrene-7-8-oxide increased squamous cell tumors in forestomach in males and females and hepatocellular tumors in males. The studies by skin application were inadequate for evaluation. In rats, styrene-7-8-oxide was tested in two studies with oral exposure by gavage (Ref. 22, 24) and one by transplacental exposure followed by gavage (Ref. 27). In both studies by gavage, squamous cell tumors of the forestomach were increased and in one of the studies mammary gland tumors where also increased in males. In the study by transplacental exposure followed by gavage, forestomach tumors where increased. IARC concluded that there is sufficient evidence for carcinogenicity of styrene and styrene-7,8-oxide in experimental animals (Ref. 5).

US NTP concluded that the evidence from studies in rats was insufficient for reaching a conclusion concerning the carcinogenicity of styrene (Ref. 1). An evaluation of the available data from eight oncogenicity studies by Cruzan et al., (Ref. 21) concluded that there was clear evidence that styrene did not induce cancer in rats. It has been proposed that the reason for lung tumor induction in mice but not rats may involve differential metabolism of styrene in the two species (Ref. 1).

Styrene – Details of carcinogenicity studies

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD_{50} (mg/kg/d) *
Ref. 16	50/sex/ group M&F B6C3F1 mouse	78 weeks, Oral Gavage	20	**2:** 150, 300 mg/kg/d	Lung/ Male ^	360
Ref. 17	70/sex/ group CD1 mouse	98-104 weeks, Inhalation	70	**4:** 20, 40, 80, 160 ppm	Lung/ Male	154[+]
Ref. 16	70/sex/ group Fischer 344 rats	78 -107 weeks, Oral Gavage	40	**3:** 500, 1000, 2000 mg/kg/d	No Tumors	NC
Ref. 21	70/sex/ group CD rats	104 weeks, Inhalation	70	**4:** 50, 200, 500, 1000 ppm	No Tumors	NC
Ref. 22	30/sex/ group SD rats	52 weeks, Inhalation	60	**5:** 25, 50, 100, 200, 300 ppm	Mammary tissue/ Female [++]	23.3
Ref. 22	40/sex/ group SD Rats	52 weeks, Gavage	40	**2:** 50, 250 mg/kg/d	No Tumors	NC
Ref. 22	40/sex/ group SD Rats	SC once, then IP 4 times at 2-month intervals	40	**1:** 50 mg (SC), 50 mg (IP)	No Tumors[¥]	NC

NC – Not Calculated, SC – Subcutaneous Injection, IP – Intraperitoneal Injection, SD – Sprague Dawley

* The TD_{50} values are taken from CPDB (Ref. 15)

^ Despite having a statistically significant dose-trend per CPDB, the author concluded that there was no convincing evidence of carcinogenicity in mice

[+] Carcinogenicity study selected for the AI calculation

[++] Author opinion: Styrene, was found to cause an increase in total (benign & malignant) and malignant
1166 mammary tumors. Cruzan et al., (Ref. 21) noted no obvious dose-response in the data. Furthermore, the
1167 study findings were not considered reliable evidence of carcinogenicity by NIH ROC (Ref. 1) and
1168 IARC (Ref. 5) noted short treatment duration and incomplete reporting of the study.
1169 [¥] Study limited to acute exposures and a non-standard study design
1170

1171 **Mode of action for carcinogenicity**

1172 A comprehensive review of the mechanisms that contribute to the carcinogenicity of styrene is
1173 presented in the IARC Monograph (Ref. 5). Taking into consideration the available *in vitro* and
1174 in vivo genotoxicity data, IARC concludes that there is strong evidence that styrene is genotoxic,
1175 and that the mechanism is relevant to humans. Styrene is metabolically activated in animals and
1176 in humans to an electrophile, styrene-7,8-oxide which interacts with nucleophilic
1177 macromolecules, such as proteins and DNA. DNA adducts are formed primarily by alkylation of
1178 N^7-guanine. Styrene-7,8-oxide DNA adducts have been observed *in vitro*, in rodents and in
1179 humans exposed to styrene. IARC also indicates that there is strong evidence that both styrene
1180 and styrene-7,8-oxide alter cell proliferation and that styrene modulates receptor-mediated
1181 effects based on increased serum prolactin in humans exposed occupationally.

1182 Other possible mechanisms contributing to the carcinogenic activity of styrene include oxidative
1183 stress, immunosuppression and chronic inflammation. The mechanism suggested by Cruzan et
1184 al. (Ref. 28) as the main cause of mice lung tumor includes styrene metabolites inducing gene
1185 expression for metabolism of lipid, lipoprotein, cell cycle and mitotic M-M/G1 phases, mild
1186 cytotoxicity and strong mitogenicity in mice lung cells, leading to excessive cell proliferation
1187 and hyperplasia. On the other hand, the authors assume that it would not be relevant in humans
1188 due to limited lung metabolism (by CYP2F2). IARC concludes that the evidence for these
1189 mechanisms of action are moderate to weak.
1190

1191 **Regulatory and/or published limits**

1192 The WHO defined a Tolerable Daily Intake (TDI) for styrene via the oral route of 7.7 µg/kg/day
1193 (i.e., 0.385 mg per day based on 50 kg body weight) from which a drinking water guideline value
1194 of 20 µg/L has been defined (i.e., 40 µg per day based on consumption of 2 L water per day)
1195 (Ref. 29). This WHO limit was based on reduced body weight gain in a two-year rat drinking
1196 water study. The US EPA oral reference dose (RfD) (Ref. 30) for styrene is 200 µg/kg/day (i.e.,
1197 10 mg/day based on 50 kg body weight), based on non-cancer endpoints. The associated US
1198 EPA drinking water limit is 100 µg/L (i.e., 200 µg per day based on consumption of 2 L water
1199 per day). The JECFA maximum TDI for styrene (Ref. 31) from migration from food packaging
1200 is 0.04 mg/kg/day (i.e., a maximum of 2 mg per day based on 50 kg body weight). A Specific
1201 Migration Limit of 60 ppm styrene into foods in polystyrene packaging (i.e., 60 mg per day
1202 assuming the consumption of 1 kg food/day for adult humans) is considered permissible in the
1203 European Union (Ref. 4).
1204

1205 **Acceptable intake (AI)**

1206 <u>Rationale for selection of study for AI calculation</u>
1207

1208 Since styrene is considered not to be a rat carcinogen, mouse lung tumors were used to derive
1209 the AI. The more sensitive TD_{50} was in the inhalation study of Cruzan et al. (Ref. 17). The AI
1210 derived from this inhalation study was considered suitable for all routes of administration as an
1211 increase in lung tumors was also seen in the carcinogenicity study in mice with gavage treatment.
1212 The AI is expected to be a conservative limit as the mouse is known to have higher levels of
1213 CYP2F enzymes in comparison to human which is key to tumor formation (Ref. 28).

Calculation of AI

Lifetime AI = $TD_{50}/50000 \times 50$ kg

Lifetime AI = 154 mg/kg/day/50000 x 50 kg

Lifetime AI = 154 μg/day

References

1. National Institutes of Health. Report on Carcinogens (NIH ROC). 14th edition. 2016; Available from: URL: https://ntp.niehs.nih.gov/ntp/roc/content/profiles/styrene.pdf

2. Capella KM, Roland K, et al. Ethylbenzene and styrene exposure in the United States based on urinary mandelic acid and phenylglyoxylic acid: NHANES 2005–2006 and 2011–2012. Environ Res 2019;171:101-110.

3. World Health Organization (WHO). Chapter 5.12 Styrene. Air Quality Guidelines – 2nd Edition. 2000; Available from: URL: http://www.euro.who.int/__data/assets/pdf_file/0018/123066/AQG2ndEd_5_12Styrene.pdf

4. Gelbke HP, Banton M, et al. Derivation of safe health-based exposure limits for potential consumer exposure to styrene migrating into food from food containers. Food Chem Toxicol 2014;64:258–69.

5. IARC (International Agency on Research of Cancer). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Styrene, stryrene-4,8-oxide and quinoline. Volume 121. Lyon, 2019.

6. NRC. Review of the Styrene Assessment in the National Toxicology Program 12th Report on Carcinogens. Washington, DC: The National Academies Press. 2014; Available from: URL: https://doi.org/10.17226/18725

7. Moore MM, Pottenger LH, House-Knight T. Critical review of styrene genotoxicity focused on the mutagenicity/clastogenicity literature and using current organization of economic cooperation and development guidance. Environ Mol Mutagen 2019;60:624-663.

8. Compton-Quintana PJ, Jensen RH, Bigbee WL, Grant SG, Langlois RG, Smith MT, Rappaport SM. Use of the glycophorin A human mutation assay to study workers exposed to styrene. Environ Health Perspect 1993;99:297-301.

9. Vodicka P, Soucek P, Tates AD, Dusinska M, Sarmanova J, Zamecnikova M, Vodickova L, Koskinen M, de Zwart FA, Natarajan AT, Hemminki K. Association between genetic polymorphisms and biomarkers in styrene-exposed workers. Mutat Res 2001;482:89-103.

10. Loprieno N, Abbondandolo A, Barale R, Baroncelli S, Bonatti S, Bronzetti G, Cammellini A, Corsi C, Corti G, Frezza D, Leporini C, Mazzaccaro A, Nieri R, Rosellini D, Rossi AM.

Mutagenicity of industrial compounds: styrene and its possible metabolite styrene oxide. Mutat Res 1976;40:317-24.

11. Beije B, Jenssen D. Investigation of styrene in the liver perfusion/cell culture system. No indication of styrene-7,8-oxide as the principal mutagenic metabolite produced by the intact rat liver. Chem Biol Interact 1982;39:57-76.

12. NTP (National Toxicology Program). 12th Report on Carcinogens. Rep Carcinog 2011; 12: iii-499.

13. NTP (National Toxicology Program). Report on Carcinogens, Fourteenth Edition.; Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service. 2016; Available from: URL: https://ntp.niehs.nih.gov/go/roc14

14. Collins JJ, Delzell E. A systematic review of epidemiologic studies of styrene and cancer. Critical Reviews in Toxicology 2018;48:443-470.

15. Carcinogenicity Potency Database (CPDB). National Institutes of Health. Carcinogenic Potency Database. Available from: URL: https://files.toxplanet.com/cpdb/index.html

16. National Cancer Institute (NCI). Technical Report Series No. 185. Bioassay of styrene for possible carcinogenicity. NCI-CG-TR-185. 1979; Available from: URL: http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr185.pdf

17. Cruzan G, Cushman JR, et al. Chronic Toxicity/Oncogenicity Study of Styrene in CD-1 Mice by Inhalation Exposure for 104 Weeks. J Appl Toxicol 2001;21:185–98.

18. Ponomarkov V, Tomatis L. Effects of long-term oral administration of styrene to mice and rats. Scand J Work Environ Health 1978;4:127–35.

19. Cruzan G, Bus JS, Banton MI, Sarang SS, Waites R, Layko DB, et al. Complete attenuation of mouse lung cell proliferation and tumorigenicity in CYP2F2 knockout and CYP2F1 humanized mice exposed to inhaled styrene for up to 2 years supports a lack of human relevance. Toxicol Sci 2017;159:413–21.

20. Brunnemann KD, Rivenson A, Cheng SC, Saa V, Hoffmann D. A study of tobacco carcinogenesis. XLVII. Bioassays of vinylpyridines for genotoxicity and for tumorigenicity in A/J mice. Cancer Lett 1992;65:107–13.

21. Cruzan G, Cushman JR, et al. Chronic Toxicity/Oncogenicity Study of Styrene in CD rats by Inhalation Exposure for 104 Weeks. Toxicol Sci 1998;46:266–81.

22. Conti B, Maltoni C, et al. Long-term carcinogenicity bioassays on styrene administered by inhalation, ingestion and injection and styrene oxide administered by ingestion in Sprague-Dawley rats, and para-methylstyrene administered by ingestion in Sprague-Dawley rats and Swiss mice. Ann N Y Acad Sci 1988;534:203-34.

1286   23. Beliles RP, Butala JH, Stack CR, Makris S. Chronic toxicity and three-generation
1287   reproduction study of styrene monomer in the drinking water of rats. Fundam Appl Toxicol
1288   1985;5:855–68.

1289   24. Lijinsky W. Rat and mouse forestomach tumors induced by chronic oral administration of
1290   styrene oxide. J Natl Cancer Inst 1986;77:471–6.

1291   25. Weil CS, Condra N, Haun C, Striegel JA. Experimental carcinogenicity and acute toxicity
1292   of representative epoxides. Am Ind Hyg Assoc J 1963;24:305–25.

1293   26. Van Duuren BL, Nelson N, Orris L, Palmes ED, Schmitt FL. Carcinogenicity of epoxides,
1294   lactones, and peroxy compounds. J Natl Cancer Inst 1963;31:41–55.

1295   27. Ponomarkov V, Cabral JRP, Wahrendorf J, Galendo D. A carcinogenicity study of styrene-
1296   7,8-oxide in rats. Cancer Lett 1984;24:95–101.

1297   28. Cruzan G, Bus JS, et al. Based on an analysis of mode of action, styrene-induced mouse
1298   lung tumors are not a human cancer concern. Reg Tox Pharm 2018;95:17-28.

1299   29. World Health Organization (WHO). Styrene in Drinking Water; Background Document for
1300   Development of WHO Guidelines for Drinking-water Quality. WHO/SDE/WHS/03.04/27.
1301   2003; Available from: URL:
1302   http://www.who.int/water_sanitation_health/dwq/chemicals/styrene.pdf

1303   30. United States Environmental Protection Agency (USEPA). Integrated Risk Information
1304   System (IRIS). Styrene (CASRN 100-42-5). 1990; Available from: URL:
1305   https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0104_summary.pdf

1306   31. Joint Expert Committee on Food Additives (JECFA). Styrene. WHO Food Additives Series
1307   19. 1984; Available from: URL:
1308   http://www.inchem.org/documents/jecfa/jecmono/v19je15.htm

1309
1310
1311
1312
1313

1314

Vinyl Acetate (CAS# 108-05-4)

Potential for human exposure

Human exposure occurs primarily in the occupational setting with very little exposure to vinyl acetate in the general population (Ref. 1). Vinyl acetate is used in the synthesis of pharmaceuticals.

Mutagenicity/genotoxicity

The mutagenicity and genotoxicity of vinyl acetate has been reviewed by Albertini (Ref. 2). Vinyl acetate is not mutagenic in the microbial reversion assay (i.e., Ames tests) in multiple strains of *Salmonella* or in *Escherichia coli* and vinyl acetate mutagenicity in mammalian cells (at the *tk* locus human TK6 cells) appears to reflect mainly chromosome level or large mutational events, but "normal growth" mutants thought to reflect smaller, gene mutations were also reported. Vinyl acetate also induced micronuclei and chromosome aberrations *in vitro* and chromosome aberrations *in vivo* and was positive in one out of five *in vivo* micronucleus studies. Small increases of micronuclei in mouse bone marrow were induced following i.p. administration, but the genotoxicity was associated with elevated toxicity and mortality (Ref. 3).

There is extensive evidence that vinyl acetate genotoxicity is mediated by its metabolite acetaldehyde. Acetaldehyde is produced endogenously and detoxification by aldehyde dehydrogenase is required to maintain intra-cellular homeostasis (Ref. 2). Given its response in mammalian cells, and rapid conversion to acetaldehyde, vinyl acetate is considered mutagenic. See Mode of Action information below for further details.

Carcinogenicity

Vinyl acetate is classified as Group 2B, possibly carcinogenic to humans (Ref. 4). There are two oral carcinogenicity reports cited in the CPDB (Ref. 5). One mouse and one rat study, in which vinyl acetate was administered in drinking water, are limited as there are only two treatment groups and less than 50 animals per group. Uterine, esophageal and forestomach tumors were observed in Swiss mice; and liver, thyroid and uterine tumors in Fisher 344 rats. A number of non-site of contact tumors (e.g., Zymbal gland, lung, liver, uterine, and mammary gland) were observed in the oral carcinogenicity studies conducted by Maltoni et al. (Ref. 6) and Lijinsky et al. (Ref. 7). These tumors in Maltoni et al. (Ref. 6) all occurred with high background incidence. Therefore, without adjusting for age, these tumor data cannot be evaluated with certainty. Squamous cell carcinoma of the oral cavity, tongue, esophagus, and forestomach were all treatment related at 5000 ppm. There were no tumors among mice administered 1000 ppm (Ref. 8). In the oldest published oral carcinogenicity study, Lijinsky et al. (Ref. 7), there are a number of deficiencies in the study design, most notably that the drinking water solutions were prepared only once per week. The authors recognized a decomposition rate of approximately 8.5% per day. Therefore, by the end of the week the animals in the 2500 ppm group, for example, were exposed to approximately 1300 ppm vinyl acetate and significant quantities of breakdown products, including acetaldehyde and acetic acid. The authors also did not purify the vinyl acetate prior to preparation of the drinking water solutions. Thus, the rats were also exposed to unspecified impurities. In addition, only 20 rats were in each group, so the statistical power for detecting true positive responses and for discriminating against false positive and false negative outcomes is compromised (Ref. 8).

In addition to the CPDB, other carcinogenicity studies are available in the literature. An oral drinking water study was conducted by the Japan Bioassay Research Centre in accordance with OECD guideline 453, including 3 treatment groups and 50 animals per group (Ref. 9, 10). Increases in tumors of the oral cavity, esophagus and forestomach in Crj:BDF1 mice and statistically significant increases of tumors in the oral cavity of female F344:DuCrj rats at all doses are reported following drinking water administration of vinyl acetate. In another lifetime study, Minardi et al. (Ref. 11) report increases in tumors in oral cavity and lips in 17-week old and 12-day old Sprague-Dawley rats also administered vinyl acetate in the drinking water. Two treatments groups are included with more than 50 animals per group for the 12-day old rats (offspring) but less than 50 per group for the 17-week old animals (breeders). The 12-day old rats are more sensitive with tumors in the oral cavity and lips, whereas an increase in tumor response is not evident in the 17-week old animals.

Finally, Bogdanffy et al. (Ref. 12) administered vinyl acetate in drinking water for 10 weeks to male and female rats that were subsequently mated. The offspring were then culled into two groups of 60 for the main study and 30 for satellite groups and exposure in the drinking water continued to 104 weeks. The authors concluded that in the offspring there were no non-neoplastic or neoplastic lesions observed that were compound related. Two squamous carcinomas were observed in the oral cavity of treated males, but the incidence of these tumors was within historical control ranges. Therefore, they were not considered related to vinyl acetate treatment.

There are two inhalation carcinogenicity reports cited in the CPDB (Ref. 5). Vinyl acetate is not carcinogenic to CD-1 mice but induces nasal tumors in Sprague-Dawley rats (Ref. 12). All but one of the 11 nasal tumors in rats (benign endo and exophytic papillomas and squamous-cell carcinomas) were observed at the terminal sacrifice at the high dose of 600 ppm, indicating a late life dependency of tumor formation. One benign tumor, of questionable relationship to exposure, was observed at the 200 ppm concentration (Ref. 12). In both species and both sexes, vinyl acetate induced morphological non-neoplastic lesions in the nasal cavity of the 200 and 600 ppm groups and in the trachea (mice only) and in the lungs of the 600 ppm groups.

Vinyl Acetate – Details of carcinogenicity studies

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD$_{50}$ (mg/kg/d)
Ref. 6	37 F and 13 M/ group Swiss Mice	2 years in drinking water	37 F, 14 M	**2:** 1000 ppm (103 mg/kg/d F and 96.3 mg/kg/d M), 5000 ppm (578 mg/kg/d F and 546 mg/kg/d M)	Uterine, Female	3920[b]
Ref. 7	20/sex/ group F344 Rat	2 years, drinking water	20	**2:** 1000 mg/L (0.1 mg/kg/d F and 0.062 mg/kg/d M), 2500 mg/L (0.04	Liver, Male	132[b]

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD_{50} (mg/kg/d)
				mg/kg/d F and 0.025 mg/kg/d M)		
Ref. 9	50/sex/ group Crj:BDF$_1$ Mice	2 years, drinking water	50	**3:** 400 ppm (63 mg/kg F and 42 mg/kg/d M), 2000 ppm (301 mg/kg/d F and 202 mg/kg/d M), 10000 ppm (1418 mg/kg/d F and 989 mg/kg/d M)	Oral cavity, Male	1854[c]
Ref. 9	50/sex/ group F344/Du Crj Rats	2 years, drinking water	50	**3:** 400 ppm (31 mg/kg/d F and 21 mg/kg/d M), 2000 ppm (146 mg/kg/d F and 98 mg/kg/d M), 10000 ppm (575 mg/kg/d F and 442 mg/kg/d M)	Oral cavity, Male	3057[c]
Ref. 11	37F and 14M/ group, Breeders (17 wk old); 53 or 83M and 57 or 87F Sprague-Dawley Rat Offspring (12 day old)	2 years, drinking water	Breeders 14M and 37F; Offspring 107M and 99F	**2:** 1000 ppm (70.6 mg/kg/d), 5000 ppm (353 mg/kg/d)[a]	Oral cavity and lips, Male	983[c]
Ref. 12	60/sex/ group Crl:CD(S	2 years, drinking water	60	**3:** 200 ppm (16 mg/kg/d F	No tumors	NC

Study	Animals/ dose group	Duration/ Exposure	Controls	Doses	Most sensitive tumor site/type/sex	TD_{50} (mg/kg/d)
	D)BR Rats			and 10 mg/kg/d M), 1000 ppm (76 mg/kg/d F and 47 mg/kg/d M), 5000 ppm (302 mg/kg/d F and 202 mg/kg/d M)		
Ref. 12	60/sex/ group Charles River CD1 Mice	2 years, inhalation	60	**3:** 50 ppm (55.3 mg/kg/d F and 46.1 mg/kg/d M), 200 ppm (221 mg/kg/d F and 184 mg/kg/d M), 600 ppm (664 mg/kg/d F and 554 mg/kg/d M)	No tumors	NC
Ref. 12	60/sex/ group Charles River CD (Sprague-Dawley) Rats	2 years, inhalation	20	**3:** 50 ppm (13.3 mg/kg/d F and 9.32 mg/kg/d M), 200 ppm (52.7 mg/kg/d F and 36.9 mg/kg/d M), 600 ppm (158 mg/kg/d F and 111 mg/kg/d M)	Nasal, Male	758[b]

NC – Not Calculated

[a] Calculated based on ICH Q3C assumptions

[b] Taken from the CPDB (Ref. 13)

[c] Study not reported in CPDB, therefore TD_{50} value calculated based on carcinogenicity data

Mode of action for carcinogenicity

Vinyl acetate has been reviewed by the European Commission's Scientific Committee on Health and Environmental Risks (SCHER), who published a Risk Assessment Report in 2008 (Ref. 1). Overall, SCHER supports the conclusion that the carcinogenic potential of vinyl acetate is expressed only when tissue exposure to acetaldehyde is high and when cellular proliferation is simultaneously elevated. This mode of action suggests that exposure levels which do not increase

1404 intracellular concentrations of acetaldehyde will not produce adverse cellular responses. As long
1405 as the physiological buffering systems are operative, no local carcinogenic effect by vinyl acetate
1406 should be expected at the NOAEL for histological changes in respiratory rodent tissues. However,
1407 the SCHER indicated that local levels at or below the NOAEL are not free of carcinogenic risk,
1408 although the risk may be negligibly low. Hengstler et al. (Ref. 8) presented the case for vinyl
1409 acetate as a DNA-reactive carcinogen with a threshold dose-response, which has also been
1410 described by Albertini (Ref. 2). Like acetaldehyde, vinyl acetate is not-mutagenic in the standard
1411 bacterial reversion assay; evidence for DNA-reactivity and site of contact carcinogenicity of
1412 vinyl acetate is that it occurs because of metabolic conversion to acetaldehyde.

1414 The genotoxicity profiles for acetaldehyde and vinyl acetate are almost identical and vinyl acetate
1415 is not active as a clastogen without the addition of carboxylesterase (Ref. 8). Therefore, the
1416 clastogenic activity of vinyl acetate is attributed to metabolic formation of acetaldehyde. At high
1417 concentrations, enzyme activities are not able to oxidize all the generated acetaldehyde, and a
1418 low pH microenvironment is the result (Ref. 12). From consistent endogenous acetic acid
1419 exposure, tissues may sustain a reduction of 0.15 units in pH following vinyl acetate treatment
1420 without adverse effects (i.e. cytotoxicity and genotoxicity) (Ref. 14). However, when this
1421 practical threshold is exceeded, DNA damage, cytotoxicity, and regenerative cellular
1422 proliferation occur, resulting in tumor formation at the site of contact.

1424 There is clear evidence for the carcinogenicity of vinyl acetate in two animal species, in both
1425 sexes and for both inhalation and oral administration. Following both oral and inhalation
1426 administration, vinyl acetate is rapidly hydrolyzed at the site of contact by carboxylesterases, to
1427 acetic acid and acetaldehyde (Ref. 3, 15). Vinyl acetate exposure produces tumors at the site of
1428 first contact along the exposure routes. The dose-response is thought to be non-linear, with the
1429 observed tumor responses reflecting the target tissue-specific enzyme activities for activation and
1430 detoxification (Ref. 2). However, as noted in the acetaldehyde monograph, there are no published
1431 measurements which would allow discrimination between the irritating effect and the potential
1432 mutagenic effect on cancer development.

1434 **Regulatory and/or published limits**
1435 For vinyl acetate, the US EPA IRIS database calculated an inhalation Reference Concentration
1436 (RfC) for non-carcinogenic effects of 0.2 mg/m^3, or 5.8 mg/day assuming a respiratory volume
1437 of 28.8 m^3. The RfC was based on a human equivalent concentration of 5 mg/m^3 derived from
1438 Owen et al. 1988 which identified both a NOAEL and a LOAEL for histopathological effects of
1439 the nasal olfactory epithelia in rats and mice in a chronic 2-year study. A total adjustment factor
1440 of 30 was applied (Ref. 16). The US EPA report did not include a carcinogenicity assessment for
1441 lifetime exposure to vinyl acetate. It is stated that RfCs can be derived for the noncarcinogenic
1442 health effects of substances that are carcinogens and to refer to other sources of information
1443 concerning the carcinogenic potential.

1445 **Permissible Daily Exposure (PDE) for oral exposure**

1446 <u>Rationale for selection of study for PDE calculation</u>

1448 Following oral administration, vinyl acetate is rapidly hydrolyzed at the site of contact by
1449 carboxylesterases, to acetic acid and acetaldehyde. Given the weight of evidence for a non-linear
1450 dose response for the carcinogenicity of both vinyl acetate and acetaldehyde following oral
1451 administration and considering high background exposure to acetaldehyde from a wide variety
1452 of foods, the oral PDE recommended is based on that derived for acetaldehyde of 2 mg/day.

1454 **PDE (oral) = 2 mg/day**

Acceptable intake (AI) for all other routes

Rationale for selection of study for AI calculation

For routes of administration other than the oral route, the inhalation carcinogenicity study in rats (Ref. 12) was used for derivation of an AI. In this study, there were 3 treatment groups with 60 animals per sex per treatment group. Animals were exposed 6 hours per day, 5 days per week for 2 years to vinyl acetate. Carcinogenicity was observed in the nasal cavity of rats, with male being the more sensitive sex. The TD_{50} for the nasal cavity in male rats is 758 mg/kg/day, as reported in CPDB. The only other carcinogenicity study that is available with vinyl acetate administered via the inhalation route in mice is negative (Ref. 12). Therefore, the rat inhalation study was selected for derivation of an AI.

Although the dose-response relationship for carcinogenicity is thought to be non-linear, as stated above, there are no published measurements which allow discrimination between a true threshold versus a non-linear inflection point. Therefore, the AI was calculated using linear extrapolation.

Calculation of AI

Lifetime AI = TD_{50}/50000 x 50 kg

Lifetime AI = 758 mg/kg/day x 50 kg

Lifetime AI (all other routes) = 758 µg/day

References

1. Scientific Committee on Health and Environmental Risks (SCHER). Risk Assessment Report on Vinyl acetate. 2008. Available from: URL: https://ec.europa.eu/health/archive/ph_risk/committees/04_scher/docs/scher_o_108.pdf

2. Albertini RJ. Vinyl Acetate Monomer (VAM) Genotoxicity Profile: Relevance for Carcinogenicity. Crit Rev Toxicol 2013;43:671-706.

3. European Chemicals Agency (ECHA). Summary Risk Assessment Report. Vinyl Acetate CASRN 108-05-4. 2008. Available from: URL: https://echa.europa.eu/documents/10162/a3c24f78-4c8d-44e9-a424-24ac30c9c8aa

4. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation 403 of carcinogenic risks to humans. Vinyl Acetate. 1995;63:443. Available from: URL: http://www.inchem.org/documents/iarc/vol63/vinyl-acetate.html

5. Carcinogenicity Potency Database (CPDB). [Online]. Available from: URL: https://files.toxplanet.com/cpdb/index.html

6. Maltoni C, Ciliberti A, Lefemine G, Soffritti M. Results of a long-term experimental study on the carcinogenicity of vinyl acetate monomer in mice. Ann N Y Acad Sci 1997;837:209-38.

7. Lijinsky W, Reuber MD. Chronic toxicity studies of vinyl acetate in Fischer rats. Toxicol Appl Pharmacol 1983;68:43-53.

1497　8.　Hengstler JG, Bogdanffy MS, et al. Challenging Dogma: Thresholds for genotoxic
1498　　　carcinogens? The case of vinyl acetate. Annu Rev Pharmacol Toxicol 2003;43:485–520.

1499　9.　Umeda Y, Matsumoto M, et al. Carcinogenicity and chronic toxicity in mice and rats
1500　　　administered vinyl acetate monomer in drinking water. J Occup Health 2004;46:87-99.

1501　10. Organization for Economic Co-operation and Development (OECD). OECD 453 Guideline
1502　　　for the Testing of Chemicals: Combined Chronic Toxicity\Carcinogenicity Studies. 2009.

1503　11. Minardi F, Belpoggi B, et al. Results of long-term carcinogenicity bioassay on vinyl acetate
1504　　　monomer in Sprague- Dawley rats. Ann N Y Acad Sci 2002:982;106-22.

1505　12. Bogdanffy MS, Tyler TR, et al. Chronic toxicity and oncogenicity study with vinyl acetate
1506　　　in the rat: in utero exposure in drinking water. Fundam Appl Toxicol 1994;23:206–14.

1507　13. Carcinogenicity Potency Database (CPDB). [Online]. Available from: URL:
1508　　　https://files.toxplanet.com/cpdb/index.html

1509　14. Nedergaard M, Goldman SA, et al. Acid-induced death in neurons and glia. J Neurosci
1510　　　1991;11:2489-97.

1511　15. Robinson DA, Bogdanffy MS, et al. Histochemical localisation of carboxylesterase activity
1512　　　in rat and mouse oral cavity mucosa. Toxicology 2002;180:209-20.

1513　16. United States Environmental Protection Agency (USEPA). Integrated Risk Information
1514　　　System (IRIS). Vinyl acetate (CASRN 108-05-4). 1990. Available from: URL:
1515　　　http://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0512_summary.pdf

Note 2

1517

1518 The calculated TD$_{50}$ for ethyl bromide is illustrated below since it was decided to use the same
1519 study data but not the TD$_{50}$ calculated by CPDB as the positive dose response was not statistically
1520 significant (see monograph for ethyl bromide).

1521

Ppm	Dose (mg/kg/day)[1]	Number of Positive Animals	Total Number of Animals
0	0	8	40
100	22.9	23	45
200	45.8	18	46
400	91.7	21	46

1522
1523
1524 A TD$_{50}$ is calculated for each dose separately with the following equation (Ref. 1, 2):

$$\frac{P - P_0}{1 - P_0} = 1 - \exp\left(-\beta \cdot D\right)$$

1525
1526 Where P is the proportion of animals with the specified tumor type observed at a certain dose (D
1527 in the equation) and P$_0$ is the proportion of animals with the specified tumor type for the control.
1528 Converting β and D into a simple linear equation results in the following:

$$\ln\left(-[\frac{P - P_0}{1 - P_0} - 1]\right) = \beta \cdot D$$

1529
1530 Plotting the results and using the slope to represent β results in the following graphs for the dose-
1531 response and β = 0.0215055234 for low dose, 0.0059671034 for mid-dose and 0.0042161616 for
1532 the high dose.

1533

1534

1535 Low Dose

1536
1537

1538

1539 Mid Dose

1540
1541

1542

1543　High Dose

1544
1545

1546

1547　The TD$_{50}$ can then be calculated as follows.

$$0.5 = 1 - \exp\left(-\beta \cdot TD_{50}\right)$$

1548
1549　Solving for TD$_{50}$ results in in the following equation.

1550

$$TD_{50\ low\ dose} = \frac{0.693}{0.0215055234}$$

$$TD_{50\ mid\ dose} = \frac{0.693}{0.0059671034}$$

$$TD_{50\ high\ dose} = \frac{0.693}{0.0042161616}$$

Therefore, the lowest TD_{50} = 0.693 / 0.0215055234 or 32.2 mg/kg/day.

References

1. Gaylor DW, Gold LS. Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. Regul Toxicol Pharmacol 1995;22:57-63.

2. Sawyer C, Peto R, Bernstein L, Pike MC. Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. Biometrics 1984;40:27-40.